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Antibiotic resistance is threatening the achievements of modern medicine and will evidentially 
lead to a situation, in which we stand helpless against common bacterial infections. The largest 
and most widely used group of antibiotics are the β-lactams. One of the major resistance 
determinants against β-lactam antibiotics is the expression of hydrolytic enzymes, called β-
lactamases (BLs). The main concern of BLs is that they are threatening the most important 
group of β-lactam antibiotics, carbapenems. 
A plausible solution to overcome the resistance introduced by BLs is the combination of 
antibiotics and inhibitors. In this thesis efforts are made towards deactivation of a BL, more 
specifically a carbapenemase, called OXA-48 by the synthesis of inhibitors.  The synthetic 
strategies and computational foundations for a new fragment library are presented within, using 
four main reactions: Suzuki-Miyaura cross coupling, reductive amination, tetrazole formation 
and ester hydrolysis.  
New inhibitors were synthesized and tested towards the activity of OXA-48, the most promising 
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1. Introduction and aim of thesis 
 “Without urgent action, we are heading for a post-antibiotic era, in which common infections 
and minor injuries can once again kill.” – 2018, World Health Organization.1 
The global need for rapid solutions to restore the potency of our last-line defense antibiotics is 
at an all-time high. A growing number of infections like tuberculosis, salmonellosis and 
pneumonia are becoming harder, and sometimes impossible, to treat.2-4 Antibiotic resistance is 
a direct threat to the achievements of modern medicine. The spread of resistance will have 
profound impact on our society and will lead to a situation in which “common infections and 
minor injuries can once again kill”.   
An important class of antibiotics are the β-lactam antibiotics. Members of this class include 
penicillins, carbapenems, monobactams and cephalosporins, all which share the common 
structural feature of a β-lactam ring.5 Several carbapenems are our last line defense against 
bacterial infections but their efficiency is now threatened by emerging resistance. 
An important cause of antibiotic resistance stems from continuous evolution of bacteria 
possessing antibiotic-deactivating enzymes. For ß-lactam antibiotics these are known as ß-
lactamases (BL) and can be divided into two sub-classes, based on their mechanism of action: 
serine - and metallo-ß-lactamases (SBL and MBLs). Furthermore, a carbapenemase is a 
carbapenem hydrolysing β-lactamase and can be a SBL or a MBLs. The focus of this thesis is 
inhibition of a serine-carbapenemase: Oxacillinase-48 (OXA-48). OXA-48 can be found in 
carbapenem-resistant Enterobacteriaceae bacteria, which are on the high priority list of 
families of bacteria that pose the greatest threat to human health, partly due to its antibiotic 
resistance properties. 
One approach to overcome the threat of β-lactamases (BL), is to synthesize new inhibitors to 
use in combination therapy with antibiotics. The goal of the inhibitor is to deactivate the β-
lactamase (or carbapenemase), and thereby maintain the bactericidal properties of the 
antibiotic. The strategy of co-administration has been applied with some success in the battle 
of carbapenem resistance, using inhibitors like avibactam, deactivating OXA-48, and 




It was previously reported by our group, that highly substituted benzoic acids show weak 
inhibition of OXA-48.7 A fragment library of 3-substituted benzoic acids and 3,5-meta-
disubstituted benzoic acids (Figure 1) was constructed, where the X-ray analysis of OXA-48: 
compound 1 (Protein Data Bank (PDB): 5QAV) complex shows that they bind in two 
overlapping binding pockets in the enzyme. The compounds showed affinity for one of the two 
binding pockets (from here on named INN and OUT pockets). However, no inhibitors with 
strong binding interaction in the OUT pocket has been reported thus far. Moreover, a docking 
study on X-ray structures of reported complexes indicated that an 2,5-substituted benzoic acid 
was more suited to occupy both pockets than the previously tested meta-disubstituted 
compounds. The fragment 4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (1) (Figure 
1) showed the best inhibition against OXA-48, and is the scaffold used in this thesis for the new 
potential 2,5-disubstituted benzoic acid inhibitors. 
 
Figure 1. Overview of the new and previous work carried out on substituted benzoic acids as inhibitors for OXA-
48. 
In light of this, the aim of the work described in this thesis was:  
• Design new fragments for OXA-48 inhibition, focusing mainly on the ortho position Y 
of 4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (1). 
• Develop a synthetic strategy to synthesize the fragments. 
• Synthesize a library of fragments for testing performed in collaboration with The 







2.1 General background  
β-lactam antibiotics are the most prescribed antibiotics to date, having numerous clinical 
applications and uses.8 The defining feature of all β-lactam antibiotics is the 3-carbon 1-
nitrogen ring known as the β-lactam ring, outlined in Figure 2. 
 
Figure 2. Oxacillin (2) with highlighted β-lactam ring. 
The β-lactam ring allows the molecule to act as a substrate for the enzyme transpeptidase in 
bacteria (also known as penicillin-binding protein), instead of a natural substrate, thereby 
blocking the enzyme and hindering the cell wall biosynthesis.9 The inhibition is covalent and 
thereby permanently blocks the enzyme. 
Bacteria expresses resistance to antibiotics in several ways, one of the major resistance 
determinants against β-lactam antibiotics is the expression of hydrolytic enzymes.10 These so-
called β-lactamases function by hydrolysing the β-lactam ring and rendering the drug inactive. 
In 2018 almost 2800 unique β-lactamases had been identified.11 They are classified into three 
or four groups, depending on the classification system. Namely, they are group 1 (class C) 
cephalosporinases; group 2 (classes A and D) broad-spectrum and extended-spectrum β-
lactamases and serine carbapenemases; and group 3 (class B) metallo-β-lactamases.12  
The focus of this thesis is on group 2, class D, the serine-carbapenemases. There are several 
proposed hydrolysis mechanisms for  serine-carbapenemases, but all share the common feature 






Scheme 1. Proposed hydrolysis mechanism of Oxacillin.
14
 
As shown in Scheme 1, the hydroxyl group of Serine 70 acts as a nucleophile that attacks the 
carbonyl carbon of the β-lactam ring, cleaving the amide bond. The opening of the ring is 
irreversible and is common for all serine-β-lactamases. Lysine 73 is one of the neighbouring 
residues important to the reaction as it accepts the proton from the hydroxyl group of Serine 
70. Other stabilizing residues include Arginine 250, which forms hydrogen bonds with the acid 
moiety of oxacillin. 
One of the most important groups of BLs regarding antibiotic deactivation is class D, often 
referred to as the oxacillinases (OXAs). The importance is due to rapid transfers of high-level 
antibiotic-resistance genes to human pathogens such as Escherichia Coli and Acinetobacter 
baumannii.16 OXAs hydrolyse penicillins, especially oxacillin (Figure 2, (2)), but are also 
known to inactivate carbapenem and some cephalosporins.17  
The mechanism explained in Scheme 1 also applies to the specific class D enzyme - 
Oxacillinase-48, which is the main target in this thesis. OXA-48 was first identified in 
Klebsiella pneumoniae, a gram-negative bacterium in Turkey in 2001.18 Since then, OXA-48 
has been identified in several other countries, including Tunisia19, Germany20, Italy21, India22, 
as well as in other bacteria such as E.Coli and the high-risk, expanding K. Pneumoniae ST307.23 
Furthermore, both Turkey and Malta have reported a pandemic situation of OXA-48 producing 
Enterobacteriaceae, underlining the threat of the enzyme.24 
In order to overcome the resistance caused by the activity of OXA-48, a combination therapy 
can be used.25-27 Herein, two drugs are administered; one β-lactamase inhibitor to block OXA-




bacteria causing an infection. The process of designing and finding new antibiotics can require 
a long time of development. In addition, designing new antibiotics can be a short-term solution 
as the bacteria could evolve and develop resistance against the new introduced antibiotic as 
well. Most of the drugs currently in the clinical pipeline are modifications on existing classes 
of antibiotics, and thereby more prone to resistance development.28 Therefore, the combination 
therapy is a practical alternative that could extend the lifetime of the already known drugs. 
Successful examples of combination therapy to inactivate carbapenemases or β-lactamases are 
meropenem/vaborbactam (deactivating KCP-2)29 or ceftazidime/avibactam (deactivating 
OXA-48).30,31 Avibactam is the first β-lactamase inhibitor without the characteristic β-lactam 
ring to reach the market as well as the first carbapenemase inhibitor to reach clinical use.32 It is 
a diazabicyclooctanone (DBO) analogue and is approved for use in combination with 
ceftazidime.33,34 Avibactam in combination with ceftazidime can be used to treat complicated 
intra-abdominal infections and urinary tract infections. In addition, avibactam is in phase three 
of clinical trials in combination with the β-lactam aztreonam.6 It has shown inhibition for a 
range of β-lactamases, including OXA-48, with the proposed mechanism shown in Scheme 2. 
 
Scheme 2.Proposed mechanism for avibactam. (A) acylation of Ser70 (B) deacylation of Ser70. Reprinted with 




Lysine 73 activates Serine 70, allowing the nucleophilic attack on one of the carbonyls of 
avibactam (Scheme 2, A) resulting in the acylation of serine 70. Assistance from serine 118 is 
necessary as it acts as a proton shuttle. The reversed process, deacylation, is show in Scheme 2 
B. Due to ring deacylation, the avibactam ring will be restored, which leaves the molecule intact 
and ready to inhibit a new enzyme.35 Avibactam is a step in the right direction, but enzymatic 
resistance to the drug has already been reported, exemplifying the ongoing war on antibiotic 
resistance.36  
There are also other molecules that show inhibition of OXA-48.6 ETX2514 (4) seen in Figure 
3, is a unique DBO that reached to clinical trials phase two in combination with sulbactam. It 
is important to note that these structures are not only interesting for OXA-48 inhibitor 
development but also show great potential for inhibition of several other β-lactamases.6 
Another interesting group having reached clinical trials against OXA-48 are cyclic boronates.37 
Several of these have shown covalent interaction with the important Serine 70. The most 
noteworthy being the combination of VNRX-5133 (Figure 3 (6), Taniborbactam) and cefepime 
that has reached clinical trials phase one.38 Vaborbactam is another cyclic boronates, which has 
reached clinical trials in the USA, but not against OXA-48.     
Penicillanic acid sulfones derivates are promising inhibitors of OXA-48 as well but are yet to 
reach clinical trials. One example of these is LN-1-255 (Figure 3, (7)). To the best of our 
knowledge, there has been no crystal structures of OXA-48 with bound LN-1-255 so far. 
However, docking studies show that there are interactions between Arginine 250, Lysine 208, 
Tyrosine 211 and Threonine 209.39 40  
The same residue interactions were observed by Lund et al. after using a fragment based drug 
discovery (FBDD) approach 41 also known as fragment based lead discovery (FBLD). A FBDD 
approach uses small molecules (<300 Da) with favourable physiochemical properties (e.g high 
water solubility, high quality interactions) in order to probe a binding site for interactions. These 
small molecules could be developed further into bigger and more potent fragments that bind 
with higher affinity. Rapid determination of structure-activity relationships is one of FBDDs 
advantages.42 It is commonly used in the early stages of enzyme inhibitor development as it can 
reveal information on moieties and structures that show inhibition, which can be further 




In 2020, Taylor et al. reported a new set of molecules based of their lead structure CDD-97 
(Figure 3, (3)).44 The hit molecule and its derivates has now been synthesized with two-fold 
increased activity compared with the initial hit. The results presented show the relevance of the 
topic and can be used for inspiration and ideas for new inhibitors.  
 
Figure 3. Overview of reported OXA-48 inhibitors. 
Our group reported a fragment library consisting of 3-substituted benzoic acids and 3,5-
disubstituted benzoic acids, showing inhibition of OXA-48.7 The tested fragments showed 
inhibition in the micro molar range (the best disubstituted fragment had IC50 = 2.9 μM).
7 In 33 
crystal structures of OXA-48 in complex with inhibitors, the fragments showed non-covalent 
bonding to Arg214, Arg250, Trp105 and Tyr211 in the binding site. As shown in Figure 4, the 
fragment does not bind directly to the important Ser70 but effectively blocks it from 






Figure 4. Fragment in binding pocket, showing relevant interactions with residues in the binding site. 
 Reprinted with permission from Akhter et al. Copyright 2018 European Journal of medical chemistry.7 
……….. 
One of the most potent and promising fragments presented by out group was the benzoic acid 
with a tetrazol-5-ylphenyl substituent (IC50= 36 μM) (Figure 5 (1, Y = H)). It showed, like most 
of the fragments, ionic bonding of the carboxylate group to the guanidine of Arg250 (Figure 
5). The interaction resembles the observed function of the sulfamate in avibactam. Furthermore, 
the tetrazole substituent formed a hydrogen bond with the guanidine group of Arg214. 
Interestingly all other fragments showed π-π-stacking with Tyr211, which has previously been 
reported as an important interaction for the inhibition of OXA-48, but is not present in the case 
of the tetrazol-5-ylphenyl substituent.45  
 
Figure 5. Interactions of 4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (1, Y = H) in the binding site of OXA-




Although having the lowest IC50 value in the mono-substituted series, fragment 1 (Y = H) 
shown in Figure 5 needs to be further improved for better inhibition. Structure based drug 
design (SBDD) can be further used to improve the fragment. SBDD includes selecting a 
structure and further evolving it to new potentially improved inhibitors based on previous 
enzyme:inhibitor complexes.  
As mentioned, X-ray analysis of the OXA-48: compound 1 (Y = H) (PDB: 5QAV) complex 
showed that the substituted benzoic acids bind in two overlapping binding pockets in the 
enzyme (INN and OUT). An assortment of fragments with decent affinity for one of the two 
binding pockets (INN) had been identified, however, no inhibitors with a strong binding 
interaction in both pockets had been reported thus far.7 Moreover, computational calculations 
based on the crystal structures performed by Akhter et al. indicated that a 2,5-substituted 
benzoic acid would be more suitable to accommodate both pockets than the previously tested 
meta-substituted compounds. Furthermore, Vallejo et al 40, and presented by Akhter et al (S. 
Akther, doctoral thesis, [2018]), suggested a future outlook for the study using 4'-(1H-tetrazol-
5-yl)-[1,1'-biphenyl]-3-carboxylic acid (1, Y = H) as a scaffold and extending in the ortho 
position. The surface representation (Figure 6) shows the proposed scaffold in the active site of 
OXA-48 with an 2-ortho substituent. 
 
Figure 6. Surface representation of 4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylic acid in OXA-48, used with 





2.2 Computational software 
In silico methods are useful tools to identify new potential fragments and trends to guide the 
synthetic development of new inhibitors. One of the advantages of targeting an enzyme for 
modulating antibiotic resistance instead of looking for brand new antibiotics, is the possibility 
to build a suitable fragment library using structure-based drug design (SBDD) based on initial 
fragment-enzyme complexes. In SBDD, the next generation of potential inhibitors are designed 
in iterative cycles from the crystal structure data of an enzyme:inhibitor complex.  
Computational modelling is a very useful tool in predicting the preferred orientation of a 
compound in a binding site and the associated estimated binding affinity or strength of 
dissociation of the compound. This strategy is known as molecular docking and is widely 
utilized in structure-based drug design, as well as a plethora of other fields.46 47  
There are many softwares available for molecular modelling and docking, each of them has 
different ways of predicting the estimated affinity and contribution to the overall inhibition. 
The most accurate programs often require heavy computational power, are complex and may 
demand a large set of knowledge to utilize them correctly.  
2.2.1  SeeSAR 
The software utilized in our SBDD study was SeeSAR, developed by BioSolveIt. It is a 
software designed to allow “interactive, visual compound prioritization as well as compound 
evolution.”48 This means that structures can be envisioned and inserted into the program, which 
not only allows to study the interactions in 3D, but also to get estimated affinity values, torsional 
properties, drug-likeliness and physicochemical parameters. SeeSAR has been used 
successfully in medicinal chemistry and other fields for similar purposes.49 50  
2.3 Relevant Reactions 
Reactions employed during this thesis were reductive amination, Suzuki-Miayura cross 
coupling (SMC), tetrazole formation and ester hydrolysis. These four main reactions are briefly 




2.3.1 Metal-catalysed Suzuki-Miyaura cross coupling 
 
Scheme 3. General Suzuki-Miyaura cross coupling reaction. 
Suzuki–Miyaura cross-coupling (SMC, Scheme 3), is the most extensively developed reaction 
to form C-C bonds and was originally reported by Akira Suzuki, Norio Miyaura and Kinji 
Yamada in 1979.51 The reaction involves cross coupling between organoborons and organic 
halides, pseudo halides or acyl electrophiles (e.g. acyl halide, anhydride, ester, amide)52, in 
presence of a nickel, iron or palladium catalyst and a base.53 Palladium catalysts are by far the 
most utilized and explored, but the cheaper nickel has also shown wide application, albeit 
requiring higher catalyst loading. Iron is also an alternative.54,55 Originally being an aryl-aryl 
connecting reaction, SMC has since been developed to facilitate a wide range of applications 
for C-C bond formation, including the synthesis of drugs, natural product and products of 
industrial value.53 Even though there are many other cross coupling reactions such as Stille 
coupling, Ullman coupling, Negishi coupling, the Suzuki coupling is the most utilized. Mild 
reaction conditions (60-80 oC), commercially available and stable boronic acid derivatives and 
the reaction compatibility towards a broad range of functional groups are a few of its 
advantages.56-58 Commonly, the reactions are performed in dioxane, DMF, toluene or water, 
often as biphasic solvent systems59-61 or without solvents as a neat reaction.62 Recently, water 
as a green medium for Suzuki couplings has attracted a noticeable attention, because of 
ecological, economical and safety reasons.59,63 However, the focus of this thesis is palladium 
catalyzed SMC to form aryl-aryl bonds, which will be discussed further in the next section. 
2.3.1.1 Palladium SMC of aryl halides 
 




The palladium-catalyzed SMC was originally used for the synthesis of biaryl compounds by 
coupling an aryl halide with a boronic acid/ acid derivative in presence of a palladium catalyst 
and a base, as shown in Scheme 4. The reaction mechanism follows a catalytic cycle of four 
steps (1, 2, 3, 4), as shown in Scheme 5, exemplified with palladium as catalyst for biaryl- 
coupling. Starting from the ligand (Ln) coordinated active species palladium (0), an aryl halide 
is added oxidatively to form an aryl-palladium (II) halide complex (A). The second step 
comprises ligand exchange between the base and the halogen to form (B) without changing the 
oxidation state of the Pd(II). The boronic acid is activated by the base to enhance polarization 
of the organic ligand and thus facilitate transmetalation (step 3). Transmetalation happens when 
the second organic moiety (Ar´) of the boron complex and the base on the palladium switch 
positions forming an aryl palladium (II) aryl complex (C) without changing the oxidation state. 
The last step (step 4) is reductive elimination. The two organic moieties are reductively 
eliminated from the Pd(II) complex and form a new C-C bond. The results is the desired Ar-
Ar´ product, and the recovered active species Pd(0). 
  
Scheme 5. Catalytic cycle of Suzuki-Miyaura cross-coupling. 
The rate of reaction is normally dependent on the oxidative addition step, which is influenced 
by the nature of the Pd catalyst. Reactivity of aryl halides (Ar-X) are dependent on the bond 
dissociation energy of the C-X bond (I > Br >Cl).55 A larger halogen will be a better leaving 




has the lowest dissociation energy among the halides and will react the fastest. Bromides are 
also reactive and useful reactants as they are readily available. Even pseudo halides such as 
triflates (OTf) can be used as replacement for the halide in a Suzuki-Miyaura cross coupling. 
In addition, electron withdrawing substituents on the aryl halide increases their reactivity while 
electron donating substituents and presence of ortho substituents would decrease their activity 
towards the oxidative addition step.65,66 Despite the slow oxidative addition in case of less 
reactive aryl halides, the choice of a suitable catalyst can help overcoming the low reaction 
rates.67 
Initial reports were based on using triaryl phosphine as ligands for the catalyst. Since then, the 
applications of many new phosphines and phosphine free ligands (Figure 7) has improved the 
efficiency and selectivity in such cross-coupling reactions.60,68 Generally, activity of the 
catalyst depends on the electronic and steric properties of the ligands around the metal center. 
Electron-donating and bulky ligands play a role in stabilizing the Ln-Pd (0) intermediate, which 
is the active species in the catalytic cycle. In addition, a smaller number of ligands coordinating 
to Pd (0) ensure faster oxidative addition of the organic halide moiety. In contrast higher 
number of ligands coordinating to Pd (0) complex leads to slower oxidative addition as the 
approach of the aryl halide is hampered. Reductive elimination has been proven to be faster in 
the case of less coordinated Pd complexes than the highly coordinated ones.58  
Catalysts based on S-Phos or XPhos (Figure 7) showed great results with electron-deficient and 
sterically hindered boronic acids, producing the desired biaryls in high yields.69 Aryl halides 
containing electron donating substituents such as NH2 or NHR have shown to be difficult 
substrates as C-X bond is more electron rich and not cleaved as easily. Nevertheless, there are 
several studies reporting Suzuki-Miyaura coupling of systems containing free amines although 
the yields were relatively low.70-72 Catalysts such as the Buchwald palladium pre-catalysts (e.g. 
Sphos G3, Xphos G2) have shown to be a good choice regarding the less active aryl halides as 






Figure 7. Examples of common Pd-catalysts and ligands used for SMC. 
2.3.2 Reductive Amination 
 
Scheme 6. Overview of reductive amination. 
Reductive amination or reductive alkylation (Scheme 6) is a wide-spread and well-known 
reaction used to form nitrogen-carbon bonds.74a,75 It proceeds via condensation of an 
aldehyde/ketone with an amine to form an iminium intermediate. The iminium is then reduced 






Scheme 7. Reaction mechanism of reductive amination with NaBH3CN. 
All the steps are reversible before the reduction of the imine. Choosing a suitable mild reducing 
agent that will readily reduce the imine is therefore important. The chemoselectivity of the 
reducing agent is the key, as the aldehydes/ketones could be reduced instead of the imine 
intermediate. The most commonly utilized reducing agents are borohydrides complexes, but 
also other agents have been reported. Examples of reducing agents are sodium 
triacetoxyborohydride (STAB)76, sodium/zinc borohydride77,78 and sodium 
cyanoborohydride.79 Alternative reducing agents have also been employed including molecular 
hydrogen79,80, silanes81, formates82, Hantzsch esters83 and photochemical reductive amination.84 
STAB is widely utilized as it is a mild hydride donor and reacts selectively with iminium ions. 
Sodium cyanoborohydride also reduces iminium ions selectively at pH 685, but at pH 3-4 will 
prefer to reduce carbonyl compounds to alcohols.85 Moreover, cyanoborohydride generates 
HCN if the conditions are acidic enough, and is moisture and air sensitive.76 Using a suitable 
reducing agent and monitoring the pH, the reaction can be carried out in a one-pot set up. 
Reduction of carbonyl groups can also be avoided by allowing enough time for the imine to 
form before adding the reducing agent. Even isolating the imine intermediate is a possibility, 
often referred to as indirect amination in comparison to the one-pot set up; direct amination.  
The acid used in reductive amination can also be interchanged. AcOH and ZnCl2 are used most 
commonly76, but there is a wide variety to choose from, including, trifluoracetic acid (TFA)86, 
HCl 87, SnCl2 




Another aspect that makes reductive amination such a highly useful, robust and broadly 
employed method is the possibility to use a variety of solvents. The most common solvents for 
this reaction are chlorinated solvents such as 1,2-dichloroethene (DCE) and dichloromethane 
(DCM).89 Non-halogenated solvents include DMF, MeOH and greener alternatives such as 
EtOAc.89 
Electron poor aldehydes and electron rich amines increase the rate of reductive amination. 
Having an aldehyde with electron withdrawing substituents makes the carbonyl of the aldehyde 
more electrophilic and thereby react faster. An amine with electron donating groups is more 
nucleophilic and is thereby preferable. Electron withdrawing groups (EWG) and electron 
donating groups (EDG) can therefore have a significant effect on the reaction. Those factors 
should be considered when composing the synthetic sequence. 
2.3.3 Tetrazole formation  
 
Scheme 8. Overview of tetrazole formation starting from a nitrile. 
Tetrazoles are five membered rings containing four nitrogen atoms and are widely used in 
pharmaceuticals as lipophilic spacers and carboxylic acid surrogates.90 They are commonly 
obtained by cycloaddition of azides and nitriles (shown in Scheme 8), but can also be 
synthesized from arylboronic acids91, aldehydes with hydroxylamine and 1-butyl-3-
methylimidazolium hexafluorophosphate (BMIM-PF6)
92, or other starting materials.93-96   
A common method for tetrazoles synthesis is combining nitrile and trimethyl silyl azide 
(TMSN3) in presence of catalytic amounts of dimethyl tin oxide.
97 The catalytic cycle of 
tetrazole formation can be divided into three major steps (Scheme 9). First the trimethylsilyl 
azide and dimethyl tin oxide react to form complex a. This makes it possible for the azide to 
attack the nitrile carbon while the nitrile group (b) is stabilised by coordinating to the remaining 
tin complex providing c. Cyclization of c proceeds via an intramolecular nucleophilic attack by 
the nitrogen stemming from the azide, to give complex d. The catalytic cycle is then completed 




complex a. All the known methods for tetrazole formation from a nitrile group use organic 
solvents, in particular, dipolar aprotic solvents such as DMF.98  
 
Scheme 9. Catalytic cycle of tetrazole formation.
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2.3.4 Ester hydrolysis  
 
 
Scheme 10. Overview of ester hydrolysis. 
Hydrolysis is a wide term used for any reaction where water cleaves one or more bonds, either 
through substitution or elimination, shown in Scheme 10. There is a plethora of examples of 
where hydrolysis occurs, but herein only acid/base catalysed ester hydrolysis is discussed. In 
the presence of water, hydrolysis of esters and amides can be performed by acid/base as 




and an acid catalyst, yielding a carboxylic acid and a primary alcohol. The acid catalyzed 
hydrolysis works with several acids, e.g. HCl and is reversible. 
 
Scheme 11. Acid catalyzed hydrolysis.74b 
Base catalysed hydrolysis on the other hand is not reversible. This is due to the carboxylic acid 
being deprotonated by the base. Additionally, the deprotonation will consume the base, making 
it important to have at least 1 equivalent. Nucleophilic attack of a hydroxyl group (base) on the 
carbonyl forces alkoxyl group to be kicked out, as it is a better leaving group than OH (Scheme 
12), resulting in the salt adduct. The base catalyzed reaction is often run in aqueous sodium 
hydroxide, but using other salts is also possible, e.g. lithium- and potassium hydroxide.  
 





3. Results and discussion 
3.1 Computational Results  
Superimposing modelled structures proposed by Vallejo et al. 40 and the crystal structures of 
OXA-48 reported by Akhter et al. 7 inspired further investigation of  possible modifications of 
the ortho position on scaffold 1. We chose to use the enzyme: substrate complexes reported by 
our group as a starting point for in silico modification of the ortho position in SeeSAR. The 
program SeeSAR was used to identify target molecules with the caveat that a short and feasible 
synthetic strategy was accessible. The crystal structure utilized for all docking was OXA-48 in 
complex with compound 1 (Y = H, Figure 8) (PDB: 5QAV). The binding site was extended 
with 39 residues to cover region close to the 2-ortho-position. 
3.1.1 A note on SeeSAR 
SeeSAR was mainly used for generating ideas, inspiration and looking for trends. The version 
used lacked important features for substrate:enzyme interaction, such as the significant π-π 
stacking of the ligand with certain amino acids (vide supra). Additionally, SeeSAR does not 
account for the flexible nature of enzymes and induced fit mechanism. Therefore, the 
evaluations for specific molecules and the affinity ranking provided by SeeSAR should be 
considered with caution. Despite these limitations, the software can give valuable insight into 
the 3D properties of the binding site as well as spark imagination and identify potential crucial 
residues for interaction. Combined with a structure-based library approach, it can be productive 






3.1.2 Exploration phase 
 
Figure 8. Scaffold (1) used for further exploration in the 2-ortho position 
To find new potential binders a SBDD approach was utilized. First the unsubstituted scaffold 1 
(Figure 8, Y = H) was inserted into the binding site of OXA-48 in silico, which revealed a 
further cavity next to the ortho position. To explore the sterically and electronical requirements 
of the 2-ortho substituent, an estimate of 1500 unique 2,5-substitued molecules were inserted. 
There were no common features between the 2-ortho-substituents added as the objective was 
to find new interactions and trends. From this “exploration-phase” three main trends were 
identified:  
1) Extending the scaffold (1) with the ortho substituent being a nitrogen-alkyl group, 
showed positive contributions by an additional hydrogen bond between the fragment 
and the enzyme residues indirectly through a water bridge (shown in Figure 9).  
2) Elongating the fragment in the 2-ortho position, by e.g. carbon chains, to reach further 
into the OUT pocket, showed more potential residue interactions and thereby overall 
higher estimated affinity.  
3) Tetrazole in general had negative torsion contributions in the cavity. Substituting the 
tetrazole for other moieties gave more flexible conformations for the molecule in the 
binding pocket. The effect was especially clear when using sulfonic acid as a 




Those trends, together with synthetic accessibility comprised the basis for the design of the new 
library of inhibitors. 
 
Figure 9. Secondary N-alkyl as 2-ortho extension. An unprecedented H-bond to Lys 116 via a water molecule was 
observed. 
3.1.3 N-alkyl substituents 
Having identified in trend 1 that nitrogen-alkyl groups increased the estimated affinity; scaffold 
1, Y = NH2 became the new proposed and improved scaffold. From a synthetic point of view, 
the new scaffold could undergo reductive amination or Buchwald-Hartwig amination to 
functionalize the 2-ortho position, and thereby offer a plausible synthetic route for obtaining 
N-alkyl substituents. To limit the potential targets identified by SeeSAR and for a more practical 
approach, all aldehydes and aryl halides on the chemical list of our research group were drawn 
in ChemDraw. The collected aldehydes/aryl halides were drawn as connected to the new 
scaffold 1, Y = NH2 through reductive amination or Buchwald-Hartwig amination before being 
docked in the binding site. The results of the hypothetical reactions and docking yielded a list 
of molecules with a plausible synthetic pathway and with new interactions in the OXA-48 


















Figure 10. Promising N-alkyl substituted fragments as suggested by SeeSAR. 
Other substituents such as N-acyls, ethers, esters alkane/alkene chains, thiols and more were 
also evaluated. None of these showed a trend towards a better estimated affinity in SeeSAR and 
did not offer for a clear synthetic route for further expansion.   
3.1.4 Elongation 
Elongating the chain to reach further into the pocket showed a trend of higher estimated affinity 
compared to those directly substituted. The goal was to keep the proposed scaffold 1, Y = NH2, 
and add a linker chain and then functionalizing it with e.g. aryls, heterocycles etc. Six different 
possible chains were studied in detail (Figure 11) as a potential new series of inhibitors. The 
six elongation chains were added to the scaffold, and then some of the aldehydes from the N-





Figure 11. Investigated carbon chain linkers. R=aryls, heterocycles etc. 
Out of these 6 chains, a with n = 2 was the most promising and showed a trend of higher 
estimated affinity whilst connected to different functionalities. It showed additional interaction 
with the ketone moiety of lysine 116 and allowed the molecules to reach other residues like 
threonine 104, shown in Figure 12. The computational data is not precise enough to state that 
certain fragments definitively bind stronger, especially as there are several factors impacting 
the affinity, but the trends observed with elongation were worth further investigation. 
 
Figure 12. Scaffold with elongated ortho substituent in the binding site of OXA-48. 
3.1.5 New meta substituents 
A sulfonic acid moiety instead of tetrazole as the meta substituent showed a clear trend of higher 
estimated affinity in the docking results. The direct substitution with UiT’s available aldehydes 




(as for 3.2.2). Out of the top 50 hits for estimated affinity, 48 of the fragments were sulfonic 
acid variants. Based on these results the fragment without an additional 2-ortho-substituent was 
identified as a possible initial target structure similar to the previous work carried out by Akhter 
et al.  
3.2 Synthetic Strategy 
Based on the docking results and ideas generated by it, several molecules were identified as 
targets. The targets were separated into three part corresponding to the three trends identified 
during the computational work of this thesis and will be addressed as follows.  
The compound series of N-alky substituted derivatives of scaffold 1 (Y = NHR) as shown in 
Figure 13 was the primary focus of our studies. The objective was to take scaffold 1 with a 2-
ortho positioned amine and extending it with aryls/hetero aryls.  
 
Scaffold 1 (Y = NHR) 
N-alkyl substituents: R = 













The extension with aryls/hetero aryls on the amine could be achieved following several possible 
synthetic strategies. Having an ortho positioned amine allowed for the use of reductive 
amination, which is a well-studied and reliable reaction. Other options were considered for the 
functionalization of the ortho-position, for example Buchwald-Hartwig amination. Buchwald-
Hartwig aminations would, however, demand couplings with sp3 carbons, which are generally 
more difficult substrates in coupling reactions.100,101 Alternatively, the reaction could be started 
from a 2,4-dihalo benzoic acid, but this might lead to regioselectivity problems and the 
important secondary amine interaction would be excluded. Thereby reductive amination was 
preferred. 
4-tetrazole-phenyl substituent in the meta position can be introduced by a sequence of Suzuki-
Miyaura cross coupling with 4-cyano-phenylboronic acid followed by tetrazole formation from 
the cyano group. The SMC and tetrazole formation had been performed on similar structures 
in our group earlier7 and was a natural synthetic choice considering the available experience.  
It also allowed us to utilize a two-step reaction reported by our group to obtain the final 
tetrazolecompound.7 Furthermore, SMC is a robust method to achieve aryl-aryl bonds and has 
shown excellent yields.52,55,57,62,67,69 Based on the reactions and the target compounds, the 
commercially available methyl 2-amino-5-bromobenzoate (9) (Figure 14) was used as starting 
material.  
 
Figure 14. Methyl 2-amino-bromobenzoate (9); starting material for the synthetic plan. 
The decision was made to start with an benzoate ester (9) instead of the free benzoic acid 
(Figure 14) since amino acids have zwitterionic characteristics and may be difficult to handle, 
isolate and purify.102 This added an extra synthetic step in form of ester hydrolysis. The 
additional step seemed favourable being possibly material efficient and time saving as the 
intermediate compounds could be handled more easily. 
When analysing the synthetic sequence, it became clear that the main diversification was 




last to keep the synthetic route as efficient as possible (strategy 1, Scheme 13). Fewer synthetic 
steps when creating a library of molecules was favourable, but it implied to introduce 
zwitterionic characteristics once the tetrazole was build up. To avoid reactivity or work-up 
problems over several steps, an alternative idea was to form the tetrazole last (strategy 2, 
Scheme 14). Two synthetic routes where thereby identified, the preferred synthetic route 1 and 
back-up route 2, shown in Scheme 13 and 14, respectively. 
 
Scheme 13. Synthetic strategy 1. 
 
 
Scheme 14. Synthetic strategy 2. 
Conducting tetrazole formation on the boronic acid (12) could additionally save time, but the 




3.2.1 Synthetic strategy for new meta substituents 
Computational docking also pointed towards sulfonic acid fragment (16) with possible positive 
contributions of the sulfonic acid substituent instead of the tetrazole moiety. The sulfonic acid 
fragment (16) could be synthesized using SMC and a commercially available boronic acid, 
which was desirable and shown in Scheme 15. 
 
Scheme 15. Proposed plan for synthesizing new meta-substituent. 
Compound 16 could be the start of a new fragment series, much like the tetrazole series shown 
in Figure 13. The same synthetic strategies (1 and 2, scheme 13 and 14 respectively) could be 
applied to obtain the series, but biological results should back up the SeeSAR results before 
more time was invested. As discussed previously, SeeSAR results should be considered 
carefully, but if the biological results of compound 16 was promising, the new series could be 
continued. 
3.2.2 Synthetic strategy for elongation 
 
 
Figure 15. Target for elongation of the 2-ortho popsition of scaffold 1 
The last target molecule (Figure 15, (17)) was an elongated version of scaffold 1. As with the 
sulfonic acid fragment, the elongated molecule (17) could be the start of a new series but 
obtaining some results to back up the SeeSAR prediction was the first priority.  Compound 17 




reductive amination with N-Boc-2-aminoacetaldehyde. Choosing this route was considered a 
good alternative for elongation, as the reductive amination could simply be carried out twice; 
once for adding the carbon linkers, and a second time after removal of the Boc group to add 
new substituents (Scheme 16). The route to obtaining the elongated product could be adapted 
the synthetic plan 1 or 2 vide supra.  
 
Scheme 16. Proposed plan for carbon chain linkers. 
3.3 Synthetic results 
3.3.1 Suzuki-Miyaura Cross coupling 
As described previously, the first step of both the synthetic strategies was to carry out Suzuki-
Miyaura cross coupling reactions before attempting reductive amination or tetrazole formation. 
Akhter et al. reported that Xphos-Pd G2 showed excellent result on a similar system to ours 
when used with K3PO4 as the base in dioxane/water at 60 
oC overnight.7 The reaction conditions 
used by Akhter et al. were not optimized for the starting materials used in this work, compound 
9 or 13. Therefore, a catalyst screening was performed in order to find tolerant reaction 





Table 1. Screening results of Suzuki-Miyaura cross coupling. 
 
Entry Catalyst (mol%) Ratio  SM:P1 
1 Pd(PPh3)4 1:2.97 
2 Pd(OAc)2 1:3.30 
3 Pd(PPh3)2Cl2 1:3.01 
4 XantPhos Pd G3 1:3.88 
5 Xphos Pd G2 1: 4.02 
General conditions: 1 = The ratios were determined by 1H NMR without and internal standard, SM = 
Start material, P = Product. 
Table 1 shows the results of the catalyst screening. The reaction model for the screening was 
set up with 1.0 equiv of methyl 2-amino-5-bromobenzoate (9) (0.2 mmol), 4-cyanophenyl 
boronic acid (12) (1.5 equiv),  catalyst (1 mol%) and potassium phosphate (3.0 equiv) , in water: 
dioxane (1:1) at 70°C overnight. Low Catalyst loading (1 mol%) was used to test their general 
efficiency. Crude NMR analysis were used to estimate the initial conversion in order to compare 
the reactivity of catalysts. 
Pd(PPh3)4 (Table 1. entry 1), showed the lowest ratio of starting material to product of (1:2.97) 
where Pd(PPh3)2Cl2 (entry 3), was a close second with a ratio of  1:3.01 starting material to 
product. The ratios of XantPhos Pd G3 and X-phos Pd G2 (entry 4 and 5 respectively) were the 
highest in favour of the desired product according to 1H NMR. This was to be expected as they 
are known to work excellently with electron deficient boronic acids as well as aryl halides 
containing electron donating substituents such as NH2.
69 
Based on crude NMR, Xphos Pd G2 seemed to be the most promising catalyst. The reaction 
mixture of entry 5 was then worked up and the pure product 13 was isolated in 40% yield. The 




water:dioxane and we expected that ester hydrolysis may be an undesired side reaction in 
aqueous basic solution. Upon changing the solvent to anhydrous THF58 the desired product was 
isolated in 72% yield after work up. Xphos Pd G2 proved to be the right choice when scaling 
up the reaction to 500 mg of methyl 2-amino-5-bromobenzoate, yielding 98% of 13 (Scheme 
17). The catalyst loading was increased to 4 mol% to ensure full conversion. The use of THF 
also prevented possible solubility problems with future coupling partners as it is more diverse 
than the biphasic medium.   
 
Scheme 17. Synthesis of methyl 4-amino-4'-cyano-[1,1'-biphenyl]-3-carboxylate (13) using SMC. 
Methyl 4-amino-4'-cyano-[1,1'-biphenyl]-3-carboxylate (13) had previously reported by Georg 
Manolikakes and co-workers.103 It was synthesized via Negishi cross-coupling between methyl 
2-amino-5-bromobenzoate and 4-cyanophenylzinc iodine using Pd(OAc)2 and S-Phos in 
anhydrous THF for 2 hours at 25°C, yielding 98%. The primary reason for choosing SMC was 
the increased scope it provided, the use of boronic acids instead of zinc iodine compounds is 
advantageous as boronic acids are more readily available and in a greater variation than zinc 
compounds, which was preferable considering the sulfonic acid moiety. In addition, boronic 
acids are safer to use and inhouse experiences with SMC reactions were present in the research 
group. 
Having successfully determined efficient conditions for the SMC, the reaction was attempted 
with the N-benzylated compound 11. The coupling of (4-cyanophenyl)boronic acid (1.5 equiv.) 
(12) with methyl 2-(benzylamino)-5-bromobenzoate (1 equiv.) (11) yielded 18 and was 





Scheme 18. Synthesis of methyl 4-(benzylamino)-4'-cyano-[1,1'-biphenyl]-3-carboxylate (18) using SMC. 
As shown in the Scheme 18 the reaction only yielded 66% of product (18) but the reaction was 
only run with 1 mol% of catalyst, due to availability, which might explain the lower conversion 
and thus drop in the yield. Due to the lower yield and strategic unfavourable order of 
transformation this approach was not pursued further. To the best of our knowledge, 18 has not 
yet been reported and the synthesis of 11, will be discussed later in the thesis. 
Before the reaction was optimized with anhydrous THF, the SMC was performed in a mixture 
of dioxane and water (1:1) with methyl 2-amine-5-bromobenzoate (9) (1 equiv.) and 4-
boronobenzenesulfonic acid (15) (1.5 equiv.) to obtain 4'-amino-3'-(methoxycarbonyl)-[1,1'-
biphenyl]-4-sulfonic acid 16 (Scheme 19). The desired product was isolated in 49% yield. It 
was detected by HRMS that the methyl ester was partially hydrolysed after coupling. 
Additionally, the yield might have been affected by the water and running the reaction in THF 
would be a potential improvement, as shown with the cyano-coupled product. Furthermore, 
different charges on the moieties of the compound make it difficult to isolate and purify the 
product, leading to potential losses. This problem is well known for amphoteric compounds as 
their physicochemical properties are highly dependent on the pH (oppositely charged groups 
will be discussed in further detail under the tetrazole, results and discussion section of this 
thesis). 
 




3.3.2 Reductive Amination 
Tetrazole formation with the nitrile containing starting material was the next step of the 
preferred synthetic plan (synthetic plan 1) followed by reductive amination. However, once the 
tetrazole moiety was introduced, the molecules became difficult to handle. Initial attempts of 
reductive amination on 14 (Scheme 20) were unsuccessful.  
 
Scheme 20. Attempted reductive amination on methyl 4-amino-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylate 
(14). 
The difficulties in handling the tetrazole compounds (14) and why the reactions were 
unsuccessful will be discussed under the tetrazole formation part of this thesis (3.3.3). The 
decision was made to use the second synthetic plan (2) from this stage on, thereby carrying out 
reductive amination right after SMC, in order to postpone introducing the tetrazole.  
For screening and optimisation of the reaction conditions, readily available 2-amino-5-
bromobenzoate was reacted with benzaldehyde or 3-hydroxy-4-methoxybenzaldehyde. 
Benzaldehyde was chosen as it is an aromatic compound without any electron withdrawing or 
donating groups, in hope that it would serve as a middle-way representative of all the different 
functionalities planned. For a more diverse substituent representative 3-hydroxy-4-
methoxybenzaldehyde was used. AcOH and ZnCl2 are both common acids used in reductive 
amination and were a natural choice. DCE is the most common solvent utilized, while EtOAc  
and IPA have both been reported to be good alternatives for a greener route.89 Microwave 
irradiation was also utilized as it had been reported as successful with other reductive amination 
reactions (e.g. ketones and anilines) and could potentially shorten the reaction time.104  
To side-step the safety aspect of using cyanoborohydride, the screening was done exclusively 
with sodium triacetoxyborohydride (STAB), a common and highly successful reducing agent 
for reductive amination.76 Other reducing agents could also be considered, but the wide scope 
of STAB, the diverse and numerous applications and high tolerance of functional groups made 




in the workup process, has very few limitations compared to other reducing agents and allows 
for a one pot set-up.76 Additionally, some reducing agents like NaH  have been known to reduce 
nitriles in the presence of acids and were avoided due to possible side reactions with the 
nitrile.105 The screening results are shown in Table 2. Interpretation of these results should go 
with the caveat that the ratios have been calculated from the starting material and product, 





Table 2. Reductive amination screening results. 
 




Time [h]  Temp [°C] Ratio 
(SM:P)1 
1 H H AcOH DCE 16 Ambient Full conv 
2 H H AcOH EtOAc 16 Ambient 1:2 
3 H H AcOH IPA 16 Ambient 1:0.4 
4 H H ZnCl2 DCE 16 Ambient Full conv 
5 H H ZnCl2 EtOAc 16 Ambient Full conv 
6 H H ZnCl2 IPA 16 Ambient 1:0.3 
7 H H AcOH DCE 0.5 100, MW 1:2.3* 
8 H H ZnCl2 DCE 0.5 100, MW 1:1.9* 
9 OMe OH AcOH DCE 16 Ambient No conv. 
10 OMe OH AcOH EtOAc 16 Ambient No conv. 
11 OMe OH AcOH IPA 16 Ambient No conv. 
12 OMe OH ZnCl2 IPA 16 Ambient No conv. 
13 OMe OH AcOH DCE 0.5 100, MW 1: 0.2 
SM = Start Material, P = Product. * =Considerable amounts of biproducts.  1 Ratios were determined 
by GCMS after work-up. 
Entries 1 (DCE), 2 (EtOAc) and 3 (IPA) showed that entry 1 (DCE) was the most suitable 
solvent choice under the proposed conditions, having full conversion, whereas 2 (EtOAc) and 




by Abdel-Magid76 that the use of AcOH and STAB can form by-products like N-acetylated and 
N-ethylated aniline substrates. Based on the work by McGonagle et al.89 it was thereby desirable 
to test ZnCl2 as acid catalyst in combination with green solvents. Entries 4 (DCE), 5 (EtOAc) 
and 6 (IPA) were set up with ZnCl2 as catalysts. The entries followed the same trend that was 
apparent with AcOH as mediator, only there was no discernible difference between DCE and 
EtOAc as both showed full conversion. IPA was clearly worse in both trials possibly due to it 
being a protic solvent. To reduce the reaction time microwave irradiation was employed (entries 
7 and 8). The microwave reactions were only set up with DCE as it was showing good 
conversion for both acids. Entries 7 and 8 contained large amounts of by-products. Furthermore, 
MS analysis of 7 and 8 exhibited the presence of a peak that might be corresponding to the free 
acid of the desired product. The conditions might have been harsh enough for acidic hydrolysis, 
but further isolation/experiments are needed to prove this hypothesis.  
Entries 9-12 showed no conversion using 3-hydroxy-4-methoxybenzaldehyde. Entry 13 
showed some conversion. It is worth mentioning that for 3-hydroxy-4-methoxybenzaldehyde, 
the reaction was not screened with DCE and EtOAc with ZnCl2, as it showed no conversion 
under the previous conditions.  
The general method seemed very suitable for the benzaldehyde reductive amination, but not 
with 3-hydroxy-4-methoxybenzaldehyde. Increasing the temperature of the reaction to 40-60°C 
could have been a possibility, but as elevated temperatures under microwave irradiation showed 
ester hydrolysis, it was thereby not attempted. A potential reason for the sluggish reactivity 
might be the electronical nature of the compound or the free alcohol group. The two electron 
donating groups of 3-hydroxy-4-methoxybenzaldehyde, lowers the reactivity. The meta-
methoxy group makes the carbon of the carbonyl group less electrophilic through resonance 
(Scheme 21), which may explain the low conversion.  
 




Entries 1, 4 and 5 all showed close to full conversion and no by-products. We therefore decided 
to use aldehyde (2 equiv.), STAB (1.7 equiv.) and ZnCl2 (2 equiv.) in DCE at ambient 
temperature as a general method in the following work. Applying this general method to the 
synthetic plan meant that it was preferable to carry out on the cyano-coupled product and with 
diverse aldehydes. Therefore, a control reaction was set up using 3-methoxybenzaldehyde (21) 
(2.0 equiv.) and the cyano-coupled starting material (13, 1.0 equiv.) (Scheme 22), in belief that 
3-hydroxy-4-methoxybenzaldehyde could be an especially difficult aldehyde and that 
aldehydes not as electron rich, might still work. The reaction yielded 96% of product (22) and 
the decision was made to continue the use of the method. 
 
Scheme 22. Synthesis of methyl 4'-cyano-4-((3-methoxybenzyl) amino)-[1,1'-biphenyl]-3-carboxylate (22) as a 
control reaction of reductive amination screening results.  on = overnight r.t = room temperature. 
Using the optimized reaction conditions, compounds 11, 22-26, in Figure 16 were synthesized. 
The reaction of 2-amino-5-bromobenzoate (9) with benzaldehyde, sodium cyanoborohydride 
and zinc chloride in MeOH had previously been reported by Levesque and Fournier 106, yielding 
99% of desired product 11. In my hands, the conditions reported by Levesque and Fournier, the 
desired product was obtained with 70% yield. Similar reactions have been carried out by Zhao 
et al. 107 with methyl 2-aminobenzoate, substituted benzaldehydes (including non-substituted 
benzaldehyde), ZnCl2 and NaBH3CN. The yields were not reported as the product was an 
intermediate. The reaction with 3-hydroxy-4-methoxybenzaldehyde or any of the compounds 





Figure 16. Reductive amination results, n.d. = Not isolated as the crude was directly submitted for tetrazole 
formation. 
Compounds 11, 22, 26 had good to excellent yields (70-96%), whilst 23 and 25 showed 
significantly lower yields (26-34%). The low yield of compound 25 might be due to sterics of 
the bulky bromo substituent. Compound 23 has an electron donating sulfur in the heterocycle, 
which makes the carbonyl carbon of the aldehyde less electrophilic. Compound 22 has excellent 
yields using an aldehyde that has an electron donating group. The cause of the high yield might 
be that the electron donating group is in the meta position and thereby therefore can’t donate 
electron density to the carbonyl group via mesomery. The same is true for compound 26.  
Compound 24 was not isolated as the Rf value of the aldehyde was indiscernible from the 
product. A very slow gradient on flash chromatography (DCM:MeOH) could not separate the 
two compounds. To remedy this, the crude was submitted directly for tetrazole formation in 
belief that the tetrazole functional group would impact the Rf value significantly. Other options 
could have been to use the aldehyde as the limiting reagent and make sure the reaction ran to 
completion or to swap the order of the reductive amination and the Suzuki-Miyaura coupling 
in hope of better separation at a later stage. 
Due to time constrictions, elongating the ortho position with a carbon linker through reductive 




3.3.3 Tetrazole formation  
After reductive amination, the next step in the synthetic plan (2, Scheme 14) was tetrazole 
formation. The tetrazole formation from a cyano group is a well-studied reaction.99,108-111 In this 
work, the conditions were based on our groups previous work with tetrazoles where those 
delivered excellent yields with similar systems.7 The compounds synthesized in the previous 
step (11, 22-26) were treated with dibutyltin (IV) oxide (0.1 eq) and trimethylsilyl azide (1.0 
eq) in DCE to provide 20, 27-31 as shown in Scheme 23. Compounds 20, 27-21 have not been 





Scheme 23. Overview of reaction conditions for tetrazole formation. * = 13% impurities found for compound 27. 
N.d = not determined. 
Compounds 14, 27 and 29 were obtained with good to excellent yields (> 75%), whilst 20 and 
28 were obtained with poor yields (< 30%). Compound 30 was submitted directly to hydrolysis 




supported by TLC and HR-MS), the compounds showed good conversion under the given 
reaction conditions, thus the poor yield for some of the compounds are probably explained by 
work-up and purification problems. For compounds 14, 20, 27, 29 the reaction was attempted 
at least twice and showed different behavior during work-up each time, making it difficult to 
devise a general work-up strategy. However, the yields increased during more attempts, which 
is likely due to a more comprehensive understanding of the structures.  
The major difference between previous work in our group and the compounds presented in this 
work was the amine functional group. The combination of an acidic tetrazole moiety and a basic 
amine moiety results in the molecule always having a charge.  The tetrazole or the amine groups 
were always ionised and the structures become amphiphilic with the hydrophobic bi-aryl 
scaffold.  Aniline and tetrazole moieties have pKa of approximately 4.9. Thereby, if pH ≥ 7 the 
compounds will mainly exist in an ionized form with negatively charged tetrazole and neutral 
amine (14c, Figure 17). On the other hand, at low pH ≤ 3, the compound will be in an ionized 
form with neutral tetrazole while the amine group is protonated and positively charged (14a, 
Figure 17). At pH between 3-7 allows the compound will exhibit different ionized forms 
including double charged compound with zwitterionic nature (14b) as shown in Figure 17.   
 
Figure 17. Modified scaffold (14) with highlighted amphiphile characteristics and different ionization forms 
according to pH, red = Hydrophilic, blue = Hydrophobic. 
As a consequence, we encountered problems when attempting extraction, running TLCs and 
column chromatography or obtaining NMR data, and the general method proposed had to be 
adapted to each individual reaction. 
Investigation towards a work-up procedure: One of the encountered problems was partial 
solubility, as some of the products precipitated in the reaction solvent and some were 
completely soluble. Compound 14, 20, 27 and 28 precipitated in dioxane during the tetrazole 




exploited for an easy work-up. Only compound 29 did not precipitate in dioxane. Thereby, the 
compounds (14, 20, 27, 28) were submitted to filtration directly upon reaction completion and 
washed with small amounts of cold dioxane to remove impurities/staring material. 
Unfortunately, it was not possible to fully isolate the pure product in form of a precipitate as a 
lot of product was observed in the filtrate as well. Several attempt of filtrating the crude with 
cold pentane and other non-polar solvents that were predicted to not dissolve the compounds 
took place. All filtration attempts with using different solvent were unsuccessful as it did not 
result in a maximum yield. Only compound 27 was able to be isolated by filtration as a pure 
precipitate with good yields (93%). The solubility inconveniences could be explained by the 
hydrophobic section of the molecule that takes precedence and partially dissolves the residue.  
Extractive work-up was then attempted on compounds 14, 20, 28-29 to prevent the loss of the 
product that could result from filtration. THF had shown the ability to dissolve most of the 
compounds and it was believed that the compounds (14, 20, 28-29) would prefer the organic 
phase. As THF is partially miscible with water, 2-methyl THF was used for extraction instead. 
Extractive work-up showed the same limitation as in the filtration step as the products were 
observed in both aqueous and organic phases. This resulted in exclusion of extraction for being 
an ineffective work-up method if maximum yields were desirable. The conclusion thereby 
became to attempt purification of the reaction mixture without additional work-up.  
Investigation towards a purification procedure: In the process to find a suitable 
chromatographic purification system, the first general trend noticed regarding finding suitable 
elution systems to the column chromatography for molecules 14, 20, 28-29 was TLC tailing. 
The compounds were unable to move on normal silica plates, due to the charges. Normal silica 
was exchanged with C-18 silica plates, but tailing was observed when using normal eluents 
such as water:acetonitrile. To mediate the tailing several eluent combinations were tested in 
order to control pH and/or deactivate the silica plates, including triethylamine, TFA, N,N-
Diisopropylethylamine (DIPEA) in water:acetonitrile. As a result of the attempts 0.1 % TFA in 
water and acetonitrile was found to be the most effective in preventing tailing, creating estimate 
pH of around 2-3 with the purpose of protonating the amine and making a net positive charge 




The method of purification for compounds 14, 20, 28-29 thereby became direct submission of 
the crude to C-18 flash chromatography with 0.1 % TFA in water and acetonitrile and flushing 
the pre-samplets with THF, if the product had solidified. Compound 29 partially solidified after 
the column chromatography within the pre-samplet whilst some was isolated from the column 
fractions. The product in the pre-sample was flushed out with THF, analysed by 1H NMR and 
13C NMR and compared to the product found in the fractions after column. The analysis clearly 
showed the presence of the product 29 in both samples. The first hypothesis was that different 
protonation states caused this intriguing behaviour, but the protonated amine was visible in both 
NMRs. The difference in separation may be caused by different behaviour of the compound in 
the column as a result of its only partial solubility in water:acetonitrile. This purification method 
was generally successful despite that some of the compounds needed several columns to yield 
the pure product. 
One particularly challenging molecule to separate in the C-18 column was compound 20, shown 
in Scheme 24. 
 
Scheme 24. Synthesis of methyl 4-(((1-methyl-1H-imidazol-5-yl)methyl)amino)-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-
3-carboxylate (20). 
Compound 20 was synthesized over two-steps, with 18 % yield. The compound behaved 
different than the other candidates when applied to the general eluent system C-18 flash 
chromatography with 0.1 % TFA in water and acetonitrile. Compound 20 did not show any 
tailing on C-18 TLC, but on the flash chromatography the compound tailed and exited the 
column over a large range of column volumes. In addition, the compound had to be submitted 
for purification several times, before it was finally isolated in 87% purity (SFC). Possible 
reasons for the column tailing are the additional charge of the imidazole ring but could also be 




an alternative to limit purification problems as tetrazoles have a highly crystalline nature,112-
114 but recrystallization was not attempted due to time constraints.   
Notes on analytical methods: After purification, finding a suitable NMR solvent also proved a 
challenge for compounds 14, 20, 27-29. Dissolving the tetrazole containing compounds in 
classic NMR solvents such as CDCl3, MeOD or D2O was not possible. Alternatively, DMSO 
and d-THF were considered as they showed better solubility of this type of compounds. Despite 
that DMSO dissolved the majority of the compounds (14, 27, 28,), it was preferably the last 
option to spare the time required for regaining the product after dissolving it due its high boiling 
point. d-THF was also a good choice as NMR solvent and at least partially dissolved most of 
the compounds. Unfortunately, d-THF is expensive and not readily available. Compound 20 
failed to dissolve in the given NMR solvents, which could be due to the 13 % of impurities that 
we did not manage to separate. d-Acetic acid was shown to be a suitable NMR solvent for 
compound 20 so, it was used to obtain the final analytical data.  
Considering all the aforementioned challenges with work-up and purification, the general 
method that seemed most suitable for similar compounds was direct application of crude C-18 
flash chromatography with 0.1 % TFA in water and acetonitrile. If solidification of product 
occurred within the pre-samplet, THF was applied successfully to elute the remaining residue. 
Note on reductive amination after tetrazole formation (strategy 1): The synthetic strategy 1 
(Scheme 13) suggests reductive amination on the tetrazole substrate 14 (Scheme 25). The 
reactions were attempted but failed due to the difficulties encountered while working with the 
charged/zwitterionic characteristics combined with the amphiphilic characteristic. The 
tetrazole-compounds could not dissolve in common solvents used for reductive amination 
(EtOAc, DCE, IPA) and the aldehyde solubility was an additional factor to consider in the 
reaction. A combination of the low conversion and general difficulties in purifications as 





Scheme 25. Attempted reductive amination on methyl 4-amino-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylate 
(14). 
Lastly, in 13C NMR analysis of the tetrazole compounds, one carbon was often missing. More 
specifically the tetrazole carbon shown in Figure 18. 
 
Figure 18. Tetrazole carbon (blue circle), often not observed in 13C NMR 
Weak or no signals of this carbon is common and has been reported previously.7,115,116 The 
carbon can however be observed with the use of HMBC, shown for compound 29 (Figure 19). 
The signal labeled tetrazole carbon shows no interactions with any visible peak from the 13C 






Figure 19. 2D NMR of compound 25 showing missing tetrazole carbon. 
3.3.4 Hydrolysis of carboxylic esters 
With the tetrazoles in hand, we continued the synthetic plan with hydrolysis to liberate the 
desired acid. The hydrolysis of carboxylic esters to carboxylic acids are well-studied.117 The 
most common conditions for basic hydrolysis of carboxylic acids are sodium, lithium and/or 
potassium hydroxide 74a,118,119 in MeOH, water or THF at ambient temperature. The most 
common condition for acidic hydrolysis is using HCl with or without a solvent.74a 







Scheme 26. Overview of ester hydrolysis reactions. 
The four compounds 32-35 (Scheme 26) were obtained by dissolving starting material in 
THF:EtOH:H2O and adding sodium hydroxide (6 equiv.). Initial attempts were made at ambient 
temperature but observing no change (TLC) the reaction temperature was increased to 60°C 
and left overnight. The mixture was purified with C-18 flash chromatography yielding poor to 
good yields (12% - 87%). The columns were flushed with 100 % water as a desalting step, 
before eluting with acetonitrile. The acids 32, 33, 34 and 35 were obtained in 41%, 12%, 87%, 
and 61% yields, respectively. The low yields can be explained by poor separation on the 
column. The solvent combination of THF:EtOH:H2O was suggested by Wei et al.
120 for 





For compound 34 a different work-up method was attempted in hopes that flash 
chromatography could be excluded to save time. For compounds soluble in organic solvents, 
the salts after hydrolysis (either HCl, sodium hydroxide etc) can be washed away into the 
aqueous phase of an extraction. The problem with the extraction of our charged compounds 
was that they were insoluble in most of the common organic solvents, resulting in the compound 
and the salt from sodium hydroxide (or other salts used) being inseparable in the aqueous phase. 
An attempt to remedy this was carried out by extracting with 2-methyl-THF and acidifying the 
aqueous phase. Crude NMR of the organic phase showed the product and butylated 
hydroxytoluene (BHT). BHT is probably introduced through the 2-methyl THF as it is a 
commonly used stabilizer to prevent the formation of peroxides in organic ethers.121 C-18 flash 
chromatography was thereby needed nonetheless, yielding 87 % product (34).  
Acid ester hydrolysis (Scheme 27) was envisioned as HCl could simply be evaporated under 
reduced pressure yielding the Cl adduct of the hydrolyzed product without any further work-up 
 
Scheme 27. Attempted synthesis of methyl 4-((3,5-dimethoxybenzyl)amino)-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-
carboxylate (32) by acid catalyzed hydrolysis. 
Having dissolved several of the tetrazole structures in acetic acid, it was suspected that stirring 
in concentrated HCl would dissolve and hydrolyze the compound yielding the desired product. 
The reaction was set up with 20 mg of 27 in 2 mL HCl but showed only partial dissolution. It 
was monitored by TLC, but after six hours there was no change and HRMS showed only 
starting material. To mediate this, the reaction temperature was increased to 60°C, which looked 
to dissolve the compound, and it was left overnight. TLC and HRMS showed no further signs 
of product so as a last attempt on the acidic hydrolysis, the reaction mixture was submitted to 
microwave irradiation for 30 min at 100°C. This resulted in the starting material decomposing 





4. Biological Results 
All the biological testing was performed in collaboration with The Norwegian Structural 
Biology Centre (NorStruct) and Universitetssykehyset Nord-Norge (UNN) and performed by 
Susann Skagseth. The compounds were tested towards OXA-48 using Nitrocefin as reporter 
substrate. The OXA-48 will hydrolyse the β-lactam ring of Nitrocefin, which shifts the 
ultraviolet absorption of Nitrocefin and allows for visual detection of β-lactamase activity. A 
diluted series of the inhibitor provides a quantitative measurement indicating how much of the 
inhibitor is needed to inhibit OXA-48s ability to hydrolyse Nitrocefin by 50%. From this data 
an IC50 can be determined.  Due to time management only two compounds were submitted for 
biological testing. The purity of the compounds submitted was determined by SFC to be >99%. 
The IC50 values for compound 32 and 35 were found to be 128 µM and 3.3 µM respectively. 





Figure 20. Compounds for biological testing with corresponding IC50 graphs. 
Based on evaluation of the previous library presented by our group it was expected that 
compound 32 would have a better IC50 value than compounds 35. The tetrazole moiety had 
shown the best affinity of all the previously tested fragments in the meta-position, and it was 




for a strong interaction with arginine 214. The meta substituents had previously mainly shown 
interaction with arginine 214, which can form one donating and one accepting hydrogen bonds. 
Tetrazole can accept one and donate one hydrogen bond, and it was thereby suspected that the 
interactions could be strong. Nitrile can just accept a hydrogen bond and was thereby predicted 
to have a lower IC50. Compound 32 additionally has an aryl substituted on its ortho positioned 
amine, which could create more interactions with the binding site. The starting scaffold without 
any ortho substituents (1) had an IC50 = 36 µM, which was improved by the ortho substituent 
on compound 32 to an IC50 = 3.3 µM. There is not enough data to conclude whether 2,5- 
substituents are better than 3,5-dimeta substituents, but the results are promising.  
To gauge the application of SeeSAR, the two compounds are compared in Figure 21. 
 
Figure 21.SeeSAR's evaluation of the two biologically tested fragments 
As we used SeeSAR in the planning of the compound library, it was interesting to compare the 
estimated affinities and experimental inhibitor activity. The estimated affinity proposed by 
SeeSAR is not directly comparable to IC50 values and must be considered thusly. As can be 
seen in Figure 21, SeeSAR estimated compound 35 to have a higher estimated affinity than 
compound 32. Since the results deviated a lot, we had a closer look at the SeeSAR models to 
understand how the software evaluated the compounds. SeeSAR evaluates that the tetrazole 
and two carbons give negative contributions to the overall affinity due to desolvation (carbons 
with red corona in Figure 22). Furthermore, it is estimated that one of the methoxy groups 
contributes positively to hindering desolvation but does not show any interactions between the 
new ortho-addition and the binding site. SeeSAR identified that compound 32 and 35 showed 






Figure 22. SeeSAR representation of compound 51 in the binding site of OXA-48. 
Compound 35, however, does not show any negative contributions in SeeSAR, as shown in 
Figure 23, and that is the reason why it is being ranked above compound 32 for estimated 
affinity. A possible explanation is that SeeSAR does not account for π-π stacking which might 
allow the fragment to reach further into the binding site compared to what might happen in the 
actual inhibition. Furthermore, SeeSAR models the enzyme to be static, which may also skew 





Figure 23. SeeSAR representation of compound 35 in the binding site of OXA-48. 
This comparison underlines what was specified in the result and discussion section of this 
thesis; the utilized version of SeeSAR is missing important parameters for accurate estimations 
and estimated affinities should be considered carefully. SeeSAR did however identify trends 
which lead to the synthesis of compounds 32, which turned out to have a good IC50. No 
conclusion can be drawn due to the limited amount of data, but the inspiration from SeeSAR in 






5. Future Outlook 
Due to time management and the interference of the COVID-19 pandemic, the project was cut 
short. Finishing the fragments already started and finalizing them for biological testing would 
be the primary objective for the future. As shown in the biological data, compound 32 inhibited 
OXA-48 with an IC50 of 3.3 µM, which is an improvement on the previously reported mono 
substituted fragments from our group and similar value to di-meta-substituted ones (2.9 µM). 
This inhibition could be an outlier but could also suggest good potential for new inhibitors with 
an ortho substituted functionalisation and should be further investigated. Attempting to 
synthesize the elongated molecules would be a high priority, given more time. The trend was 
apparent from the SeeSAR results that elongated molecules would reach new potential binding 
residues in the binding site and could provide increased inhibition. 
Furthermore, it would be interesting to co-crystalize the inhibitors and the OXA-48 enzyme for 
X-ray analysis to gauge whether the amine contributed to the inhibition. If, as hypothesized 
through the computational work, it does contribute, the synthetic route herein could be used to 
synthesize a larger library. If the amine does not contribute to the inhibition of OXA-48, 
substituting it for a functionality that does not introduce zwitterionic/charged/amphiphile 
characteristics, would be favourable. Additionally, the computational results presented herein 
could be of great guidance to future fragment design either by expanding the proposed library 
or creating new ones.  
Lastly, for a new series of inhibitors, it could be interesting to investigate a benzhydrylamine 
(36) scaffold and develop it using structure-based drug design (Figure 24). Based on SeeSAR 
docking, benzhydrylamine could obtain an estimated affinity in the micro molar range and 
interact with the all-important serine 70 as well as serine 118, shown in Figure 25. A di-meta 
substituted scaffold (37) looks especially promising as SeeSAR suggest that the compounds 
could directly interact with serine 70, tyrosine 211, whilst di-meta substituents like carboxylic 
acid, tetrazole and phosphonic acid could reach threonine 209, serine 118 and arginine 250 and 
214 (shown in Figure 26). The combination of these interactions shows a trend in all submitted 
fragments of consistent nanomolar inhibition. A preliminary biological test with commercially 





Figure 24. Benzhydrylamine (36) scaffold transformation to new possible future fragment (37). 
 
  

















The spread of bacteria possessing antibiotic-deactivating enzymes is a major threat to society 
and is a growing problem. As the spread continue, it will be increasingly important to have new 
inhibitors and scaffolds in the pipeline. Our contribution is summarized below.  
Three main objectives were identified for this thesis. First, designing new fragments for OXA-
48 inhibition, focusing   mainly on the 2-ortho position (Y) of 4'-(1H-tetrazol-5-yl)-[1,1'-
biphenyl]-3-carboxylic acid (1). In chapter 3.1 We show that SeeSAR was used to explore the 
active site of OXA-48 and design a library of potential OXA-48 inhibitors. The work herein 
can be used for further inspiration in future projects by expanding the library proposed in this 
thesis or for new libraries.  
In chapter 3.2 we show our efforts towards the second aim; to develop a synthetic strategy for 
the target fragments. The molecules identified in the computational section can be synthesized 
using the synthetic strategy 2 presented in Scheme 14, which was preferable to synthetic 
strategy 1 (Scheme 13) due to the difficulties of handling the proposed compounds. The 
synthesis developed here consisted of Suzuki-Miyaura cross coupling, reductive amination, 
tetrazole formation and ester hydrolysis.  
The third and last aim was to synthesize a library of fragments for biological testing. The 
synthesis results and discussion can be seen in chapter 3.3 and the biological testing can be seen 
chapter 4. Two compounds (32 and 35) were delivered for biological testing (performed by 
Susann Skagseth) against the OXA-48 enzyme, with IC50 of 3.3 µM and 127 µM. The inhibition 
is very promising, and more analogs are desirable and in the pipeline. In total, 15 new 
compounds were synthesized and characterized by 1H NMR, 13C NMR, HR-MS, SFC*, IR* 
and melting point* (* = not for all the compounds) 
All the initial aims were met and yielded a potent inhibitor towards OXA-48, with micromolar 
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8. Experimental Procedures 
Unless otherwise noted, purchased chemicals were used as received without further 
purification. Solvents were dried according to standard procedures over molecular sieves 4 Å. 
Flash chromatography was carried out on silica gel 60 (230−400 mesh) or by automated normal 
phase flash chromatography (n-heptane/EtOAc) with the sample preloaded on a Biotage 
SampletⓇ cartridge (SP-1 Biotage system). Purification by reversed phase (RP) C18 column 
chromatography (H2O with 0.1% TFA/MeCN with 0.1% TFA) was performed on an automated 
purification PuriFlash Biotage module with the sample preloaded on a SampletⓇ cartridge. 
Thin layer chromatography was carried out using Merck TLC Silica gel 60 F254 and visualized 
by short-wavelength ultraviolet light or by treatment with an appropriate stain. GC-MS 
chromatograms were recorded on a Thermo Scientific Trace GC Ultra with a Thermo Scientific 
ITQ 110 detector (Column: Supelco SLB-5 ms, 30m x 0 ,2 mm x 0,2 µm film thickness, flow 
1.0 ml/min helium). Microwave reactions were conducted with Anton Paar Monowave 300 
microwave synthesis reactor. NMR spectra were obtained on a Bruker Advance 400 MHz NMR 
spectrometer at 20 °C. The chemical shifts are reported in ppm relative to the solvent residual 
peak (CDCl3: δH 7.26 and δC 77.16; MeOH-d4: δH 3.31 and δC 49.00; D20: δH 4.79; DMSO-
d6: δH 2.51 and δC 39.52, THF-d8: δH 3.58, δH 1.73 and δC 67.57, δC 25.37; acetic-acid-d4: 
δH 11.65, 2.04 and δC 178.99, 20.0). 13C NMR spectra were obtained with 1H decoupling. Data 
are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, dt = double triplet, m = multiplet), coupling constant (J, Hz) and corresponding amount 
of protons. High-resolution mass spectra (HRMS) were recorded from MeOH solutions on an 
LTQ Orbitrap XL (Thermo Scientific) either in negative or in positive electrospray ionization 
(ESI) mode. Melting points were measured using Stuart SMP50 automatic melting point 
detector. The purity of all compounds submitted to biological testing was determined to be ≥ 








Unless otherwise noted, the following gradient was used on the Waters UPC, SFC system: 
 Time (min) Flow (mL/min) % A  %B 
1 Initial 1.000 75.0 25.0 
2 2.00-3.50 1.000 60.0 40.0 
4 3.70-4.50 1.000 75.0 25.0 
A: CO2 B: 0.1% NH3 in MeOH. 
8.1 Suzuki-Miayura Cross coupling  
8.1.1 General Procedure 1 
The aryl halide (1.0 eq), boronic acid (1.5 eq) and tripotassium phosphate (2.0 – 4.5 eq) were 
mixed together in anhydrous THF. Before and after adding the air sensitive catalyst, Xphos Pd 
G2 (0.02 eq), the mixture was degassed with argon. The mixture was stirred at 70°C for 16 
hours under argon atmosphere. The resulting mixture was diluted with water and filtered 
through Celite, before adding additional water and extracting the aqueous phase with CHCl3 (3 
times). The combined organic phases were dried over MgSO4, filtered and concentrated under 
reduced pressure before the crude material was purified by flash chromatography with EtOAc 
and n-hexane or water and acetonitrile, to yield the pure biaryl product.  
8.1.1.1 4'-Amino-3'-(methoxycarbonyl)-[1,1'-biphenyl]-4-sulfonic acid (16)  
 
Methyl 2-amino-5-bromobenzoate 9 (15.2 mg, 0.07 mmol), 4-boronobenzenesulfonic acid 15 
(20 mg, 0.10 mmol), tripotassium phosphate (63 mg, 0.3 mmol) and Xphos Pd G2 (3.1 mg, 
0.004 mmol) in water:dioxane (2 mL,1:1) and purified with reverse phase C-18 flash 




DMSO -d6) δ 8.00 (t, J = 2.3 Hz, 1H), 7.65 – 7.58 (m, 3H), 7.52 – 7.47 (m, 2H), 6.88 (d, J = 
8.7 Hz, 1H), 3.83 (s, 3H). 13C NMR (101 MHz, DMSO -d6) δ 167.7, 150.2, 146.2, 139.5, 132.5, 
128.3, 126.6, 126.2 (2C), 124.7 (2C), 117.6, 109.5, 51.6. HRMS (ESI) m/z: [M-H]- calculated 
for C14H12O5NS 306.0438; found 306.0431. 
8.1.1.2 Methyl 4-amino-4'-cyano-[1,1'-biphenyl]-3-carboxylate (13) 
 
 
Methyl 2-amino-5-bromobenzoate (9) (500 mg, 2.17 mmol), 4-cyanophenylboronic acid (12) 
(479 mg, 3.26 mmol) potassium triphosphate (1.38 g, 6.52 mmol) and Xphos Pd G2 (68.4 mg, 
0.09 mmol) in anhydrous THF (7 mL) and purified with normal phase flash chromatography, 
yielded 13 (0.536 g, 2.12 mmol, 98%) as a beige solid. m.p. 146-148°C.  1H NMR: (400 MHz, 
CDCl3) δ 8.16 (d, 1H), 7.70 – 7.62 (m, 4H), 7.55 (dd, J = 8.6, 2.3 Hz, 1H), 6.81 (d, J = 8.6 Hz, 
1H), 3.92 (s, 3H). 13C NMR (101 MHz, CDCl3-d) δ 168.3, 150.2, 144.9, 132.8 (2C), 132.7, 
130.2, 127.4, 126.7 (2C), 119.3, 117.8, 111.4, 110.0, 52.0. HRMS (ESI) m/z: [M+H]+ 
calculated for  C15H13O2N2 253.0973; found 253.0972. IR (cm-1): 3480, 3365, 2955, 2229, 
1681, 1603, 1633, 1495, 1447. 









8.1.1.3 Methyl 4-(benzylamino)-4'-cyano-[1,1'-biphenyl]-3-carboxylate (18)  
 
 
Methyl 2-(benzylamino)-5-bromobenzoate (9) (185 mg, 0.58 mmol), 4-cyanophenylboronic 
acid (12) (127 mg, 0.87 mmol), potassium triphosphate (367.9 mg, 1.73 mmol) and Xphos Pd 
G2 (10 mg, 0.01 mmol) in  anhydrous THF (7 mL) and purified with normal phase flash 
chromatography, yielded 18 (131 mg, 0.06 mmol, 66%) as a white solid. m.p. 158.1-165°C.   
1H NMR (400 MHz, CDCl3) δ 8.58 – 8.25 (s, 1H), 8.23 (d, J = 2.3 Hz, 1H), 7.69 – 7.59 (m, 
4H), 7.57 (dd, J = 8.8, 2.4 Hz, 1H), 7.41 – 7.33 (m, 4H), 7.33 – 7.26 (m, 1H), 6.76 (d, J = 8.8 
Hz, 1H), 4.52 (s, 2H), 3.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.0, 151.2, 145.0, 138.5, 
133.2, 132.8, 130.6, 129.0, 127.6, 127.3, 126.6, 125.7, 119.5, 112.9, 111.0, 109.8, 52.1, 47.3. 
HRMS (ESI) m/z: [M+Na]+ calculated for C22H18O2N2Na and C22H19O2N2 365.124 and 
343.1443; found 365.1271 and 343.1452 respectively.  
8.2 Reductive Amination 
8.2.1 Reductive Amination Screening Data 
The reductive amination screening was carried out with GCMS with no internal standard, on 
the following reaction(s): 
 
Scheme 28. Reductive amination screening, R1= H or MeOCH3, R2 = H or OH. 
The reaction mixture was extracted with NaHCO3 and EtOAc and the organic phase was 




submitting for GC-MS analysis. The injection volume used was 1.0 µl. with the following 
program: GC-Program: 80(1)/25/300(5), Injector 230°C, flow 1.0 ml/min, MS-transfer line 
300°C. The results from GCMS analysis provided a graph from, which the area was used to 
find an estimate of conversion, seen in Figure 27. 
 
Figure 27. GCMS result of reductive amination screening (entry 2, R1 = H, R2 = H) 
Compound 9 had a Rf. value of 7.91. Benzaldehyde (10) had a Rf. of 3.84. 3-Hydroxy-4-
methoxybenzaldehyde had a Rf. value of 7.01 whilst the product (11) of entry 2 (R1 = H, R2 = 
H) had a Rf value of 10.78. No internal standard was used, meaning the Rf values deviated 
slightly for each run. The estimated conversion was based on the area of the curve of the starting 





8.2.2 General Procedure 2 
The amine (1.0 eq), aldehyde (2.0 eq) and zinc chloride (1.7 –2.0 eq) were mixed in DCE. After 
10 minutes of stirring, STAB or NaBH3CN (1.7 eq) was added and the mixture was left to stir 
at room temperature overnight. When TLC indicated completion, the resulting crude mixture 
was quenched with saturated aqueous NaHCO3 solution and extracted with EtOAc (3x), before 
drying the combined organic phases over MgSO4. The solution was concentrated under reduced 
pressure and purified by flash chromatography on silica gel (EtOAc and n-hexane) to yield the 
desired secondary amine. 
8.2.2.1 Methyl 2-(benzylamino)-5-bromobenzoate (11) 
 
 
Methyl 2-amino-5-bromobenzoate (9) (200 mg, 0.87 mmol), zinc chloride (202 mg, 1.48 
mmol), NaBH3CN (92.7 mg, 1.48 mmol) and freshly distilled benzaldehyde (10) (177 µL, 
1.74 mmol) were refluxed for additional 20 hours after stirring at room temperature overnight, 
as starting material was still present according to TLC. After purification this yielded a beige 
solid, compound 11 (0.194 g, 0.61 mmol, 70%). 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 
8.04 (d, J = 2.5 Hz, 1H), 7.39 – 7.31 (m, 5H), 6.52 (d, J = 9.0 Hz, 1H), 4.43 (d, J = 5.6 Hz, 2H), 
3.87 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 168.1, 149.9, 138.4, 137.3, 133.9, 128.9, 127.4, 
127.1, 113.7, 111.7, 106.3, 51.9, 47.1. HRMS (ESI) m/z: [M+H]+ calculated for C15H15O2N
81Br 








carboxylate  (22) 
 
 
Methyl 4-amino-4'-cyano-[1,1'-biphenyl]-3-carboxylate (13) (140 mg, 0.55 mmol) and 3-
methoxybezaldehyde (134.9 µl, 1.11 mmol), zinc chloride (151 mg, 1.11 mmol) and STAB 
(200 mg, 0.94 mmol) in DCE (3.5 mL) yielded thin, beige, solid sheets of 22 (198 mg, 0.53 
mmol, 96%). m.p. 162-166°C.   1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 2.3 Hz, 1H), 8.19 
(d, J = 2.4 Hz, 1H), 7.65 – 7.56 (m, 4H), 7.53 (dd, J = 8.8, 2.4 Hz, 1H), 7.25 – 7.21 (m, 1H), 
6.96 – 6.90 (m, 1H), 6.88 (s, 1H), 6.81 – 6.76 (m, 1H), 6.72 (d, J = 8.8 Hz, 1H), 4.46 (s, 2H), 
3.88 (s, 3H), 3.77 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 168.9, 160.1, 151.0, 145.0, 140.1, 
133.1, 132.7, 130.5, 130.0, 126.5, 125.7, 119.4, 119.3, 113.0, 112.9, 112.7, 110.9, 109.7, 55.4, 
52.0, 47.2. HRMS (ESI) m/z: [M+Na]+ calculated for C23H20O3N2Na 395.1369; found 
395.1377. 
8.2.2.3 Methyl 4'-cyano-4-((3,5-dimethoxybenzyl)amino)-[1,1'-biphenyl]-3-
carboxylate  (26) 
 
 
Methyl 4-amino-4'-cyano-[1,1'-biphenyl]-3-carboxylate (13) (200 mg, 0.79 mmol) and 3,5-
dimethoxybenzaldehyde (263 mg, 1.59 mmol), zinc chloride (216.1 mg, 1.59 mmol) in DCE (4 




MHz, CDCl3) δ 8.28 (t, J = 5.8 Hz, 1H), 8.12 (d, J = 2.4 Hz, 1H), 7.59 – 7.50 (m, 4H), 7.46 
(dd, J = 8.8, 2.4 Hz, 1H), 6.63 (d, J = 8.8 Hz, 1H), 6.43 (d, J = 2.3 Hz, 2H), 6.28 (t, J = 2.3 Hz, 
1H), 4.35 (d, J = 5.7 Hz, 2H), 3.82 (s, 3H), 3.69 (s, 6H). 13C NMR (101 MHz, CDCl3)δ 168.8, 
161.3, 151.1, 144.9, 141.1, 133.1, 133.0, 130.4, 126.4, 125.5, 119.3, 112.7, 110.7, 109.6, 105.0, 
99.0, 55.4, 51.9, 47.2. HRMS (ESI) m/z: [M+Na]+ calculated for C24H22O4N2Na 425.1472; 
found 425.1472. IR(cm-1): 3357, 2948, 2847, 2221, 1685, 1596, 1503.  
8.2.2.4 Methyl 4'-cyano-4-((thiophen-2-ylmethyl)amino)-[1,1'-biphenyl]-3-
carboxylate  (23) 
 
 
Methyl 4-amino-4'-cyano-[1,1'-biphenyl]-3-carboxylate (13) (150 mg, 0.59 mmol), 3,5- 
thiophene-2-carbaldehyde (111 µl, 1.19 mmol), zinc chloride (162.1 mg, 1.19 mmol) and STAB 
(214.2 mg, 1.01 mmol) in DCE (3.5 mL), yielded 23 (71 mg, 0.20 mmol, 34%) as a white solid.  
1H NMR (400 MHz, DMSO) δ 8.30 (t, J = 5.9 Hz, 1H), 8.18 (d, J = 2.2 Hz, 1H), 7.87 – 7.73 
(m, 5H), 7.41 (d, J = 5.2 Hz, 1H), 7.10 (d, J = 3.4 Hz, 1H), 7.01 – 6.95 (m, 2H), 4.75 (d, J = 
5.8 Hz, 2H), 3.85 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 168.8, 150.7, 144.9, 142.0, 133.1, 
132.7, 130.5, 127.1, 126.5, 125.9, 125.2, 124.8, 119.3, 112.5, 111.0, 109.8, 52.0, 42.4. HRMS 









Methyl 4-amino-4'-cyano-[1,1'-biphenyl]-3-carboxylate (13) (150 mg, 0.59 mmol), 2-bromo-
6-fluorobenzaldehyde (241.4 mg, 1.19 mmol), zink chloride (162.1 mg, 1.19 mmol) and STAB 
(224.3 mg, 1.01 mmol)  in DCE(3.5 mL), yielded 25 (67 mg, 0.15 mmol, 26%) as a white 
solid.1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 8.20 (d, J = 2.3 Hz, 1H), 7.65 (m, 5H), 7.46 
– 7.35 (m, 1H), 7.17 (q, J = 7.5 Hz, 1H), 7.10 – 7.02 (m, 2H), 4.64 (s, 2H), 3.88 (d, 3H).13C 
NMR (101 MHz, CDCl3). δ 168.64, 161.4 (d, J = 250.3 Hz), 150.5, 144.8, 133.1, 132.6, 130.5, 
130.3 (d, J = 9.5 Hz) ,129.1 (d, J = 3.6 Hz), 126.39, 125.9 – 125.7 (m), 125.6, 119.2, 115.2, 
114.9, 112.1 (d, J = 2.8 Hz), 110.9, 109.6, 51.8,40.5 (d, J = 3.4 Hz). HRMS (ESI) m/z: [M+H]+ 
calculated for C22H17O2N2F
81Br 441.0430; found 441.0431 112.14.  
8.3 Tetrazole formation 
8.3.1 General Procedure 3 
The nitrile (1.0 eq) was dissolved in anhydrous dioxane or DCE in a 10 ml microwave vial. 
Dibutyltin (IV) oxide (0.1 eq) and trimethylsilyl azide (1.0 eq) were added and the vial was 
flushed with argon. The reaction was heated in the microwave at 150°C for 1 hour. A second 
portion of dibutyltin (IV) oxide (0.1 eq) and trimethylsilyl azide (1.0 eq) was added before the 
vial was flushed with argon and resubmitted to the microwave for 1 more hour at 150°C. The 
resulting mixture was concentrated under reduced pressure before dissolving in diethyl ether. 
The organic phase was extracted with 2 N aqueous sodium hydroxide (3x). The aqueous phase 
was acidified with 4N aqueous HCl to pH = 1 and extracted with EtOAc. The organic layer was 
washed with brine and dried over MgSO4 before concentrating under reduced pressure and 
purified with C-18 flash chromatography. Due to the unpredictable nature of amino-acid 




8.3.1.1 Methyl 4-amino-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylate (14) 
 
 
Methyl 4-amino-4'-cyano-[1,1'-biphenyl]-3-carboxylate (13) (100 mg, 0.40 mmol), dibutyltin 
(IV) oxide (19.7 mg, 0.08 mmol) and trimethylsilyl azide ( 104.9 µl, 0.79 mmol) in  dioxane (3 
mL), yielded 14 as a white solid (100 mg, 0.34 mmol, 86%). m.p. 132-135°C.   1H NMR (400 
MHz, DMSO-d6) δ 8.11 – 8.03 (m, 3H), 7.77 (d, J = 8.3 Hz, 2H), 7.72 (dd, J = 8.7, 2.4 Hz, 1H), 
6.92 (d, J = 8.7 Hz, 1H), 6.88 (s, 2H), 3.84 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 167.7, 
151.2, 141.4, 132.4, 128.5, 127.3, 126.0, 125.4, 123.5, 117.4, 109.0, 51.6. HRMS (ESI) m/z: 





Methyl 4'-cyano-4-((3,5-dimethoxybenzyl)amino)-[1,1'-biphenyl]-3-carboxylate (26) (165 mg, 
0.41 mmol), dibutyltin (IV) oxide (20.4 mg, 0.08 mmol) and trimethylsilyl azide (108.6 µl, 0.82 
mmol) in DCE (4 mL), yielded 27 as a yellow solid (170 mg, 0.38 mmol, 93%). This reaction 
deviated from the general procedure. The product precipitated from the reaction mixture and 
filtration was attempted. The residue was washed with 2-methyl THF, followed by dioxane, 




both filtrate and precipitate. The residue that did not pass through with DCE was pure and 
yielded 170 mg, and further purification of filtrate was not attempted. m.p. 190-193°C.   1H 
NMR (400 MHz, THF-d8) δ 8.28 (t, J = 5.7 Hz, 1H), 8.16 (d, J = 2.4 Hz, 1H), 7.99 – 7.90 (m, 
2H), 7.66 – 7.52 (m, 3H), 6.69 (d, J = 8.9 Hz, 1H), 6.43 (d, J = 2.3 Hz, 2H), 6.24 (t, J = 2.2 Hz, 
1H), 4.34 (d, J = 5.7 Hz, 2H), 3.76 (s, 3H), 3.61 (s, 6H). Residual THF (δ 3.62 (m) and 1.78 
(m)) and MeOH (δ 3.28 (s)) is observed. 13C NMR (101 MHz, THF-d8) δ 169.5, 162.5, 152.0, 
143.7, 142.6, 133.7, 130.5, 128.6, 128.5, 128.3 (2C), 127.2 (2C), 127.1, 113.6, 111.5, 105.8, 
99.7 (2C), 55.6, 52.0, 47.9. HRMS (ESI) m/z: [M-H]- calculated for C24H22O4N5 322.0263; 





Methyl 4-amino-4'-cyano-[1,1'-biphenyl]-3-carboxylate (13) (200 mg, 0.79 mmol) 1-methyl-
1H-imidazole-5-carbaldehyde (175 mg, 1.59 mmol), zinc chloride (216 mg, 1.59 mmol) and 
STAB (286 mg, 1.35 mmol) in 4 ml DCE, yielded a crude mixture of methyl 4'-cyano-4-(((1-
methyl-1H-imidazol-5-yl)methyl)amino)-[1,1'-biphenyl]-3-carboxylate (24), which was used 
for tetrazole formation without any further purification. 344 mg crude mixture, dibutyltin (IV) 
oxide (49.4 mg, 0.20 mmol) and trimethylsilyl azide (263 µl, 2.00 mmol) yielded the title 
compound (20) over two steps after purification with reverse phase flash chromatography, as a 
white solid (56.9 mg, 0.15 mmol, 18%). 1H NMR (400 MHz, DMSO-d6) δ 8.18 (d, J = 2.4 Hz, 
1H), 8.06 (d, J = 8.1 Hz, 2H), 7.98 (t, J = 5.6 Hz, 1H), 7.83 (dd, J = 8.7, 2.5 Hz, 1H), 7.78 – 
7.68 (m, 3H), 7.07 (d, J = 8.9 Hz, 1H), 6.96 (s, 1H), 4.56 (d, J = 5.5 Hz, 2H), 3.85 (s, 3H), 3.66 
(s, 3H).13C NMR (101 MHz, acetic acid-d4) δ 170.0, 157.0, 150.7, 144.0, 137.9, 134.2, 132.9, 
131.1, 129.1, 128.4, 127.6, 122.8, 119.5, 113.5, 112.5, 52.6, 37.2, 34.4. HRMS (ESI) m/z: [M-




1190. SFC Purity: 87%. Structure is proven with additional 2D NMR (see appendix). Residual 
acetone can be observed. There are 4 aliphatic carbons impurities which is highly likely the 





Methyl 4'-cyano-4-((thiophen-2-ylmethyl)amino)-[1,1'-biphenyl]-3-carboxylate (23) (70 mg, 
0.20 mmol), Dibutyltin (IV) oxide (10 mg, 0.04 mmol) and trimethylsilyl azide (53.2 µl, 0.40 
mmol) in anhydrous dioxane, yielded 28 as white solid (22 mg, 0.06 mmol, 30%) after washing 
the precipitate with CHCl3, deviating from the general procedure. m.p. 122.3-224.5°C.  1H 
NMR (400 MHz, THF-d8) δ 8.41 (t, J = 5.9 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.09 (d, J = 8.0 
Hz, 2H), 7.88-7.74 (m, 3H), 7.28 (d, J = 5.1 Hz, 1H), 7.05 (d, J = 3.4 Hz, 1H), 6.98 – 6.90 (m, 
2H), 4.73 (d, J = 5.3 Hz, 2H), 3.87 (s, 3H). 13C NMR (101 MHz, THF-d8) δ 169.4, 151.5, 143.8, 
143.6, 133.8, 130.5, 128.3 (2C), 127.7, 127.5, 127.3(2C), 125.9, 125.4, 124.7, 113.5, 111.8, 
52.0, 42.9. HRMS (ESI) m/z: [M-H]- calculated for C20H16O2N5S 390.1026; found 390.1019. 






3-carboxylate  (29) 
 
 
Methyl 4'-cyano-4-((3-methoxybenzyl)amino)-[1,1'-biphenyl]-3-carboxylate (22) (198 mg, 
0.53 mmol), dibutyltin (IV) oxide (26.5 mg, 0.12 mmol) and trimethylsilyl azide (140.8 µl, 1.06 
mmol) in DCE (3 mL), yielded 29, as a white solid (165 mg, 0.40 mmol, 75%). Deviating from 
the general procedure in that both organic and aqueous layer was combined and purified with 
reverse-phase flash chromatography. m.p. 201-204°C.   1H NMR (400 MHz, THF-d8) δ 8.42 
(t, J = 5.8 Hz, 1H), 8.29 (d, J = 2.3 Hz, 1H), 7.90 (m, 4H), 7.70 (dd, J = 8.7, 2.2 Hz, 1H), 7.21 
(t, J = 7.9 Hz, 1H), 6.94 (d, J = 6.9 Hz, 2H), 6.85 – 6.75 (m, 2H), 4.52 (d, J = 5.2 Hz, 2H), 3.88 
(s, 3H), 3.75 (s, 3H). 13C NMR (101 MHz, THF-d8) δ 169.6, 161.4, 152.0, 143.7, 141.9, 133.8, 
130.5, 130.5, 128.3, 127.2, 127.2, 124.6, 120.0, 113.7, 113.6, 113.3, 111.5, 55.5, 52.0, 
47.7.HRMS (ESI) m/z: [M-H]- calculated for C23H20O3N5 414.1570; found 414.1561. IR (cm-
1): 3379, 2840, 1681, 1611, 1573, 1499, 1439. SFC Purity: 98%. 
 
8.4 Hydrolysis 
8.4.1 General procedure 4 
The ester (1.0 eq) was dissolved in a 2:1:1 mixture of THF:H2O:EtOH. Sodium hydroxide (3.0-
6.0 eq) was added and the reaction was left to stir overnight at 60°C. The reaction mixture was 







8.4.1.1  4-Amino-4'-cyano-[1,1'-biphenyl]-3-carboxylic acid (35) 
 
 
Methyl 4-amino-4-cyano- [1, 1-biphenyl]-3-carboxylate (13) (40 mg, 0.16 mmol) in a 2 ml 
2:1:1 mixture of THF:H2O:EtOH (2 mL, 1:0.5:0.5) and sodium hydroxide (20 mg, 0.48 mmol) 
yielded 35 as a white solid (23 mg, 0.10 mmol, 61%). m.p. 214.7-215°C.  1H NMR (400 MHz, 
D2O) δ 8.21 (s, 1H), 8.15 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.69 (dd, J = 8.7, 2.3 
Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H). 13C NMR (101 MHz, D2O) δ 170.9, 158.2, 152.1, 142.7, 
132.9, 130.0, 128.0, 127.1 (2C), 126.6 (2C), 124.6, 118.2, 111.0. HRMS (ESI) m/z: [M-H]- 
calculated for C14H9O2N2 237.0665; found 237.0670. IR (cm-1): 3312, 3476, 3365, 2229, 1678, 
1622, 1603.  SFC Purity: < 99%. The SFC method deviated from the standard (method used 
is shown in the appendix). 
8.4.1.2 4-Amino-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (34) 
 
 
Methyl 4-amino-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylate (23 mg, 0.08 mmol), in a 
THF:H2O:EtOH (4 mL, 2:1:1)and sodium hydroxide (9.36 mg, 0.23 mmol) yielded 4b as a 
white solid (19 mg, 0.10 mmol, 87%). m.p. > 300°C.  1H NMR (400 MHz, D2O + THF-d8) δ 
8.30 (d, J = 2.3 Hz, 1H), 8.24 (d, 2H), 7.84 (d, 2H), 7.78 (dd, J = 8.7, 2.4 Hz, 1H), 7.04 (d, J = 
8.7 Hz, 1H). Residual THF (δ 3.80 (m) and 1.93 (m)) is observed. 13C NMR (101 MHz, D2O 
+ THF-d8) δ 170.9, 158.2, 152.1, 142.7, 132.9, 130.0, 128.0, 127.1, 126.6, 124.6, 118.2, 111.0. 








Methyl 4-(benzylamino)-4'-cyano-[1,1'-biphenyl]-3-carboxylate (24 mg, 0.10 mmol), 
dibutyltin (IV) oxide (5  mg, 0.02 mmol) and trimethylsilyl azide (26.2 µl, 0.20  mmol) in DCE 
(2 mL), yielded methyl 4-(benzylamino)-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-carboxylate, 
which was directly stirred in sodium hydroxide (1M, 9 ml) and diethyl ether (5 mL) for 20 
minutes for  hydrolysis to occur. The mixture was concentrated under reduced pressure and 
purified by a C-18 column, yielding 33, as a sand-white solid (3 mg, 0.01 mmol, over two steps 
12%). 1H NMR (400 MHz, MeOH-d4) δ 8.28 (d, J = 2.4 Hz, 1H), 8.04 (d, 2H), 7.72 – 7.66 (m, 
3H), 7.41 – 7.31 (m, 5H), 7.29 – 7.20 (m, 1H), 6.81 (d, J = 8.8 Hz, 1H), 4.52 (s, 2H). Residual 
acetone (δ 2.2 (s) is observed 13C NMR (101 MHz, MeOH-d4) δ 172.1, 160.1, 152.1, 143.5, 
140.5, 133.8, 131.3, 129.7, 128.5, 128.2, 128.2, 127.7, 127.3, 126.1, 113.6, 112.3, 47.7. 
Residual acetone (30.6 ppm) (s) is observed. HRMS (ESI) m/z: [M-H]- calculated for 
C21H16O2N5 370.1308; found 370.1309.  
 
8.4.1.4 4-((3,5-Dimethoxybenzyl)amino)-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-







(27) (80 mg, 0.18 mmol). in a 4 ml 2:1:1 mixture of THF:H2O:EtOH and sodium hydroxide 
(43.1 mg, 1.08 mmol) yielded 32 as a white solid (32 mg, 0.07 mmol, 41%). . m.p: 
decomposed. HRMS (ESI) m/z: [M-H]- calculated for C23H20O4N5 430.1517; found 430.1510. 
1H NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 2.4 Hz, 1H), 8.06 (d, J = 8.3 Hz, 2H), 7.85 – 
7.73 (m, 3H), 6.80 (d, J = 8.9 Hz, 1H), 6.53 (d, J = 2.3 Hz, 2H), 6.39 (t, J = 2.3 Hz, 1H), 4.47 
(s, 2H), 3.72 (s, 6H). 13C NMR (101 MHz, DMSO-d6) δ 169.8, 160.7, 150.5, 142.0, 141.8, 
132.6, 129.6, 127.5, 126.1, 124.9, 121.8, 112.7, 110.8, 105.0, 98.4, 55.1, 45.9. IR (cm-|): 3365, 







9.1 Suzuki Miyaura cross coupling Spectra 








abhm100634frag5finalester_neg #1-9 RT: 0.02-0.24 AV: 9 NL: 1.40E8
T: FTMS - p ESI Full ms [100.00-800.00]























































abhm10069final_pos #1-10 RT: 0.00-0.25 AV: 10 NL: 2.63E7
T: FTMS + p ESI Full ms [200.00-500.00]















































C 14 H16 O2 N = 230.1176
-0.0713 mmu
307.1053
C 16 H16 O3 N2 Na = 307.1053











abhm100617spot2_pos2 #1-9 RT: 0.02-0.24 AV: 9 NL: 2.87E7
T: FTMS + p ESI Full ms [100.00-600.00]


















































9.2 Reductive amination Spectra 








abhm100621final_pos #1-9 RT: 0.02-0.26 AV: 9 NL: 1.68E6
T: FTMS + p ESI Full ms [200.00-500.00]







































C 22 H18 O2 N2 Na = 365.1271
-0.7720 mmu
343.1443





C 23 H12 O2 N4 Na = 399.0863
0.7915 mmu














ABHM100644_final_pos #1-8 RT: 0.01-0.26 AV: 8 NL: 5.36E4
T: FTMS + p ESI Full ms [100.00-600.00]















































160.0054 287.1469 468.1893175.9851 494.2694
349.1837














ABHM100638_CRUDE_2_final_pos #1-7 RT: 0.02-0.24 AV: 7 NL: 3.29E4
T: FTMS + c ESI Full ms [100.00-700.00]
































































abhm100645possibly_pos #1-5 RT: 0.01-0.07 AV: 5 NL: 7.76E6
T: FTMS + p ESI Full ms [115.00-500.00]



























































abhm100649_final_good_pos #1-9 RT: 0.02-0.25 AV: 9 NL: 6.04E6
T: FTMS + p ESI Full ms [100.00-650.00]
















































9.3 Tetrazole formation 







abhm10066final_neg #1-9 RT: 0.02-0.25 AV: 9 NL: 4.10E7
T: FTMS - p ESI Full ms [200.00-500.00]






















































abhm100639_Final_neg #1-9 RT: 0.01-0.25 AV: 9 NL: 6.64E7
T: FTMS - p ESI Full ms [100.00-800.00]




































































ABHM100640_FINAL_neg #1-7 RT: 0.02-0.25 AV: 7 NL: 3.64E5
T: FTMS - p ESI Full ms [120.00-700.00]










































































abhm100646_couldbefinal_nomass_neg #1-6 RT: 0.02-0.15 AV: 6 NL: 8.30E7
T: FTMS - p ESI Full ms [200.00-800.00]

































































abhm100647_aqphase_final_neg #1-9 RT: 0.01-0.25 AV: 9 NL: 1.62E6
T: FTMS - p ESI Full ms [120.00-800.00]


























































9.4 Hydrolysis Spectra 










abhm100635_FINAL_nomasslock_neg #1-8 RT: 0.00-0.20 AV: 8 NL: 2.19E7
T: FTMS - p ESI Full ms [113.00-600.00]







































C 14 H9 O2 N2 = 237.0670
-0.4715 mmu
373.0409
C 15 H17 O2 N3 Br Na = 373.0407
0.1972 mmu 475.1402
C 21 H22 O3 N7 Na S = 475.1408
-0.5897 mmu248.9598
295.0250







Waters UPC, SFC system, deviating from standard gradient: 
 Time (min) Flow (mL/min) % A  %B 
1 Initial 1.000 98.0 2.0 
2 2.00-3.50 1.000 60.0 40.0 
4 3.70-4.50 1.000 98.0 2.0 













abhm100606HACTUALfinal_neg #1-10 RT: 0.01-0.24 AV: 10 NL: 1.13E6
T: FTMS - p ESI Full ms [100.00-500.00]







































C 14 H10 O2 N5 = 280.0840
-0.8315 mmu
394.0756





















ABHM100630muligfinal_neg #1-6 RT: 0.01-0.15 AV: 6 NL: 2.17E6
T: FTMS - p ESI Full ms [100.00-800.00]


































































abhm100651good_neg #1-8 RT: 0.01-0.24 AV: 8 NL: 1.72E6
T: FTMS - p ESI Full ms [113.00-700.00]

































































9.5 Suzuki-Miyaura Screening Spectra 















9.6 SeeSAR experimental 
The version of the software used was SeeSAR version 9.2; BioSolveIT GmbH, Sankt Augustin, 
Germany, 2019, https://www.biosolveit.de/SeeSAR.  
The enzyme used was 5QAV from PDB, which is the OXA-48 enzyme in complex with 
compound 1. SeeSAR defines compound 1 with the following name: L43_D_301, which was 
used to define the binding site automatically by SeeSAR. The binding site was lacking enough 
dept in the OUT pocket and additional residues were thereby added, for a total of 39, which can 
be seen in Figure 28.  
 
Figure 28. Custom defined binding site around L43_D_301 inhibitor 
By using the “docking mode” molecules were drawn and imported from Chemdraw. On 




torsion quality, molecular clashes, optibrium properties, Ligand lipophilic efficiency (LLE) and 
more. The results were resulted in a list, seen in Figure 29.  
 
Figure 29. Example list of SeeSAR results 
 
 
  
 
 
  
 
 
 
  
 
 
 
